Der Mu-Opioidrezeptor-Polymorphismus 118A>G : ein genetischer Modulator von Opioideffekten by Oertel, Bruno Georg
 
Mu-opioid receptor gene variant OPRM1 118A>G: 
A genetic modulator of opioid effects 
Dissertation 
zur Erlangung des Doktorgrades 
der Naturwissenschaften 
vorgelegt beim Fachbereich Chemische und Pharmazeutische Wissenschaften 
der Johann Wolfgang Goethe-Universität 
in Frankfurt am Main 
von 
Bruno Georg Oertel 
aus Neuburg an der Donau 
Frankfurt am Main (2008) 
(D 30) 
 
II 
 
 
 
 
 
 
 
 
Vom Fachbereich Chemische und Pharmazeutische Wissenschaften der Johann Wolfgang Goe-
the-Universität als Dissertation angenommen. 
 
 
 
 
Dekan:   Prof. Dr. Harald Schwalbe 
 
 
 
Gutachter:  Prof. Dr. Dieter Steinhilber 
    Prof. Dr. Dr. Gerd Geißlinger 
 
 
 
Datum der Disputation: 13.05.2008   
  Table of Contents   
 
III 
1  INTRODUCTION ............................................................................................................... 1 
1.1  Pain .......................................................................................................................................... 1 
1.1.1  Nociception ................................................................................................................................ 1 
1.1.2  Pain perception ......................................................................................................................... 2 
1.2  Mu-opioid receptors .............................................................................................................. 4 
1.2.1  Structure, anatomical localization and function of the µ-opioid receptor ............................ 5 
1.2.2  Pharmacological effects of opioid analgesics .......................................................................... 7 
1.2.3  Mu-opioid receptor coding gene OPRM1 ................................................................................. 7 
1.2.4  Mu-opioid receptor gene variant OPRM1 118A>G  .................................................................. 9 
1.3  Aim of the study  .................................................................................................................... 10 
2  MATERIAL AND METHODS ....................................................................................... 11 
2.1  Enrolment of healthy subjects ............................................................................................ 11 
2.2  Collection of human brain tissue  ........................................................................................ 11 
2.3  Genetic screening for carriers of SNP OPRM1 118A>G .................................................... 11 
2.4  Study designs ........................................................................................................................ 14 
2.4.1  Investigation of pain-related brain activation during alfentanil administration in non-
carriers and homozygous carriers of OPRM1 118A>G SNP  ............................................................... 14 
2.4.2  Investigation of µ-opioid receptor expression and function in pain processing brain 
regions of non-carriers and carriers of OPRM1 118A>G SNP ........................................................... 15 
2.4.3  Investigation of the therapeutic range of alfentanil in non-carriers and carriers of OPRM1 
118A>G SNP .......................................................................................................................................... 18 
2.5  Assessment of opioid effects in healthy humans .............................................................. 19 
2.5.1  Administration of alfentanil by computerized infusion ....................................................... 19 
2.5.2  Analysis of alfentanil plasma concentrations ........................................................................ 20 
2.5.3  Assessment of pain .................................................................................................................. 21 
2.5.3.1  Transcutaneous electrical stimulation  .......................................................................... 21 
2.5.3.1.1  Procedure  ................................................................................................................... 21 
2.5.3.1.2  Psychophysical quantification of pain and analgesia ............................................. 21 
2.5.3.2  Painful gaseous carbon dioxide stimuli applied to the nasal mucosa......................... 22 
2.5.3.2.1  Procedure  ................................................................................................................... 22 팠˝
  Table of Contents   
 
IV 
2.5.3.2.2  Psychophysical quantification of pain and analgesia ............................................. 23 
2.5.3.2.3  Quantification of pain and analgesia by means of functional magnetic resonance 
imaging (fMRI) ............................................................................................................................. 24 
2.5.4  Assessment of respiratory depression .................................................................................. 26 
2.5.4.1  Provoking hyperventilation by means of CO2 re-breathing ........................................ 26 
2.5.4.2  Monitoring of spontaneous respiration ........................................................................ 27 
2.5.5  Assessment of opioid related medical symptoms ................................................................. 28 
2.6  Assessment of µ-opioid receptor expression and function in post mortem human 
brain tissue ........................................................................................................................................ 28 
2.6.1  OPRM1 mRNA expression analysis ........................................................................................ 28 
2.6.2  Tissue preparation for binding assays  ................................................................................... 29 
2.6.3  Protein concentration analysis  ............................................................................................... 29 
2.6.4  [3H]-DAMGO binding assays ................................................................................................... 30 
2.6.4.1  Saturation binding .......................................................................................................... 30 
2.6.4.2  Displacement binding  ..................................................................................................... 30 
2.6.5  [35S]-GTPγS binding assays ..................................................................................................... 32 
2.7  Data analysis ......................................................................................................................... 33 
2.7.1  Investigation of pain-related brain activation during alfentanil administration in non-
carriers and homozygous carriers of OPRM1 118A>G SNP  ............................................................... 33 
2.7.2  Investigation of µ-opioid receptor expression and function in pain processing brain 
regions of non-carriers and carriers of OPRM1 118A>G SNP ........................................................... 34 
2.7.3  Investigation of the therapeutic range of alfentanil in non-carriers and carriers of OPRM1 
118A>G SNP .......................................................................................................................................... 35 
3  RESULTS .......................................................................................................................... 39 
3.1  Pain-related brain activation in non-carriers and homozygous carriers of OPRM1 
118A>G SNP during alfentanil administration ............................................................................. 39 
3.1.1  Pain-related brain activation in non-carriers of SNP ORPM1 118A>G ................................ 39 
3.1.2  Effects of increasing alfentanil concentrations on pain-related brain activation in non-
carriers of SNP ORPM1 118A>G .......................................................................................................... 39 
3.1.3  Consequences of SNP OPRM1 118A>G for alfentanil effects on pain-related brain 
activation............................................................................................................................................... 45 
3.2  Mu-opioid receptor expression and function in pain processing brain regions of non-
carriers and carriers of OPRM1 118A>G SNP ................................................................................ 47  ٚ
  Table of Contents   
 
V 
3.2.1  OPRM1 mRNA expression ....................................................................................................... 47 
3.2.2  [3H]-DAMGO binding assays ................................................................................................... 49 
3.2.2.1  Saturation binding .......................................................................................................... 49 
3.2.2.2  Displacement binding  ..................................................................................................... 50 
3.2.3  [35S]-GTPγS binding assays ..................................................................................................... 51 
3.2.4  Mu-opioid receptor expression related receptor signaling ................................................. 52 
3.3  Therapeutic range of alfentanil in carriers and non-carriers of OPRM1 118A>G SNP 54 
3.3.1  Plasma concentrations of alfentanil ....................................................................................... 54 
3.3.2  Analgesic effects of alfentanil ................................................................................................. 55 
3.3.3  Respiratory depressive effects of alfentanil .......................................................................... 58 
4  DISCUSSION.................................................................................................................... 60 
5  CONCLUSION .................................................................................................................. 67 
6  ABSTRACT ...................................................................................................................... 68 
7  DEUTSCHE ZUSAMMENFASSUNG ........................................................................... 70 
8  LITERATURE .................................................................................................................. 75 
9  APPENDIX ....................................................................................................................... 84 
9.1  Abbreviations ....................................................................................................................... 84 
9.2  Danksagung .......................................................................................................................... 86 
9.3  Curriculum vitae .................................................................................................................. 87  ٚ
  Introduction   
 
1 
1  Introduction 
The µ-opioid receptor is the primary target structure of most clinically used opioid analgesics. 
Activation of the receptor is accountable for the major part of the wanted and unwanted ef-
fects of opioid analgesics. The common genetic µ-opioid receptor variant N40D (allelic fre-
quency 8.2-17%), coded by the single nucleotide polymorphism 118A>G of the µ-opioid recep-
tor gene OPRM1 (OPRM1 118A>G SNP), has been repeatedly associated with a decrease of the 
wanted and unwanted effects of opioid analgesics in carriers of this variant. The aim of the 
here presented thesis was to identify the mechanism by which the OPRM1 118A>G SNP dimin-
ishes the opioid effects and to explore its consequences for the pain treatment. This knowl-
edge is important for the clinical pain therapy with opioid analgesics because it guarantees its 
effectiveness and safety when used in carriers of the OPRM1 118A>G SNP. 
1.1  Pain 
The individual experience of pain is generated by a complex network of cortical and subcortical 
brain regions and comprises sensory, qualitative and emotional components [1]. Thus, the 
International Association for the Study of Pain (IASP) defines pain as ‘an unpleasant sensory 
and emotional experience that is associated with actual or potential tissue damage, or de-
scribed in terms of such damage’. In contrast, nociception describes the body system that car-
ries the information about a noxious stimulus to the spinal cord and brain. Nociception even-
tually leads to pain perception, but frequently occurs below the level of consciousness without 
the sensation of pain. The other way around, pain is usually caused by a noxious stimulus but 
may also be experienced in the absence of such stimuli. 
1.1.1  Nociception 
Depending on the point of origin, pain is differentiated in somatic and visceral pain. Somatic 
pain originates from the head, torso or extremities and visceral pain originates from the inner 
organs. A special kind of pain is the neuropathic pain, which is the result of nerve damage. 
Nociception starts with activation of peripheral nociceptors by a noxious stimulus. Nociceptors 
are free nerve endings of myelinated Aδ- or unmyelinated C- fibres and their axons terminate 
in lamina IV-VI or lamina I-II, respectively, of the spinal cord dorsal horn. Somatosensory sig-
nals are mainly transmitted by myelinated Aδ, whereas the viscerosensory signals are trans-
mitted by unmyelinated C- fibres [2].  
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In the spinal cord dorsal horn, the nociceptive signal is transmitted via synaptic transmission to 
a second neuron, which ascends either to the thalamus via the spinothalamic tract (STT), to 
the medulla and brainstem via the spinoreticular (SRT) and spinomesencephalic (SMT) tracts, 
or to the hypothalamus via the spinohypothalamic tract (SHT). Since there are so many func-
tional and anatomical subdivisions of the thalamus, the spinothalamic pathway can be further 
differentiated. Lamina I STT axons project to the ventral posterior lateral nucleus (VPL), the 
posterior part of the ventral medial nucleus (VMpo), the ventral posterior inferior nucleus (VPI) 
and the ventral caudal division of the medial dorsal nucleus (MDvc). Lamina V STT axons ter-
minate in the ventral posterior nucleus (VP), the ventral posterior inferior nucleus (VPI), ven-
tral lateral nucleus and intralaminar nuclei. In the brainstem regions, the nociceptive signal is 
transferred to a third neuron, which projects to the cortical and subcortical areas that are es-
sential for pain perception. That is, midline thalamic nuclei (VMpo and MDvc) neurons project 
to limbic cortical areas such as the anterior cingulate cortex (ACC) and the insular cortex (IC) 
while more posterior lateral nuclei (VPL and VPI) of the thalamus project to the primary and 
secondary somatosensory cortices (SI and SII, respectively). SRT axons terminate in the nucleus 
raphe magnus and nucleus gigantocellularis of the formatio reticularis by which the variant 
receptors affect in the medulla oblongata. From there, neurons project into the medial thala-
mus, hypothalamus (HT) and the amygdala (AMYG) [3]. SMT axons terminate mainly in the 
midbrain periaqueductal gray (PAG), nucleus cuneiformis (Cnf) and nucleus pretectalis ante-
rior. Neurons of these areas then further project to medial prefrontal and insular cortices and 
hypothalamus [4].  
1.1.2  Pain perception 
The cortical and subcortical areas activated by the several ascending pain transmission path-
ways during painful stimulation include the somatosensory cortices (SI and SII), primary motor 
cortex (M1), supplementary motor area (SMA), insular cortex (IC), anterior, middle and post-
erior cingular cortex (ACC, MCC and PCC), prefrontal cortex (PF), basal ganglia (BG; consisting 
of putamen, caudate nucleus, nucleus accumbens and globus pallidus), posterior parietal cor-
tex (PPC), amygdala (AMYG), hypothalamus (HT) and thalamus (VMpo, MDvc, VPL; Figure 1; [5, 
6]). Activation of these regions by nociceptive stimuli results in the conscious perception of 
pain. Thus, these areas are also referred to as the “pain matrix”. It is assumed that each area 
plays a different role in the process of pain perception. For example, the somatosensory cor-
tices SI and SII are deemed to be responsible for discrimination of the location and intensity of 
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painful stimuli, thus the sensory component of pain [7], whereas the amygdala as part of the 
limbic system is primarily thought to have a role in the affective dimension of pain, creating 
feelings of unpleasantness and emotions [8]. Prefrontal and parietal cortical areas are believed 
to be related to cognitive variables, such as memory or stimulus evaluation [7]. Motor areas 
such as the primary and supplementary motor cortices and caudate nucleus (basal ganlia) 
seem to be related to pain evoked movements or suppression of movement [9]. The insular 
cortex and the anterior cingulate cortex seem to be multi-integrative structures that play a role 
for both sensory and affective dimension of pain, but also for motor, cognitive and autonomic 
functions [10]. 
All areas are more or less interconnected by association fibers, creating a complex network of 
communicating regions within the brain. For example, there is a ventrally directed cortico-
limbic pathway proceeding from SI and SII to the posterior parietal cortical areas and to the IC 
and from IC to amygdala, perirhinal cortex and hippocampus [11]. This pathway converges on 
limbic and subcortical structures that are also directly targeted by ascending spinal pathways 
and is suggested to integrate somatosensory input with other sensory input such as vision or 
audition and with learning and memory [11].  
The individual pain perception depends on the activation pattern of the interconnected brain 
regions and changes in the activation pattern results in an alteration of pain perception. Dis-
ruption of the cortical and subcortical regions that form the pain matrix, and the pathways 
between them, can result in serious conditions. For example, patients after ischaemic injury 
(i.e. stroke) affecting the posterior insula and SII suffer from a decrease of pain and tempera-
ture sensation [12]. Furthermore, opioid receptor expression in the pain network plays a very 
important role for pain perception. For example, in patients suffering from the poststroke pain 
syndrome after an ischaemic brainstem injury, a massive reduction of opioid receptor binding 
sites in the posterior thalamus and posterior insula and SII, respectively, has been demonstrat-
ed [13].  
   
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Figure 1: Cortical and sub-cortical brain regions involved in pain perception, their inter-connectivity 
and ascending pain transmission pathways. Brain regions involved in pain perception include the pri-
mary  and  secondary  somatosensory  cortices  (S1  and  S2,  red  and  orange),  anterior  cingulate  (ACC, 
green), insula (blue), thalamus (yellow), prefrontal cortex (PF, purple), primary and supplementary mo-
tor cortices (M1, blue and SMA), posterior parietal cortex (PPC), posterior cingulate (PCC), basal ganglia 
(BG,  pink),  hypothalamus  (HT),  amygdale  (Amyg),  parabrachial  nuclei  (PB)  and  periaqueductal  grey 
(PAG). The schematic was originally published in 2000 [5] and modified in 2005 [6]. 
 
 
1.2  Mu-opioid receptors 
One of the most important neurotransmitters involved in pain and nociception are the endo-
genous  opioid  peptides  including  endorphins,  enkephalines,  dynorphines,  and  the  recently 
discovered  endomorphins  and  nociceptin  (not  to  be  mixed  up  with  the  above  mentioned 
´nociception`). Endorphins, enkephalines, dynorphines and nociception are derived from dif-
ferent precursor proteins, the proopioimelanocortin (POMC), proenkephalin (PENK) and pro-
dynorphin (PDYN) and pronociceptin. Their targets are four separate receptors, the μ- (mu), δ- 
(delta) and κ- (kappa) receptors, and the opioid receptor-like protein (ORL1) [14, 15].  
It has been shown that µ-opioid receptor-knockout mice do not respond to morphine with 
analgesia, respiratory depression, constipation, physical dependence reward behaviours, or 
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immunosuppression [16]. Morphine – and also other opioid analgesics – bind not only µ-opioid 
receptors but also δ- or κ-receptors [17]. However, no behavioral responses related to δ- or κ-
opioid receptor activation was observed in the µ-opioid receptor-knockout mice during mor-
phine treatment, although these receptors were still present in these mice [16]. Thus, µ-opioid 
receptors are essential for the action of morphine and other clinically used opioid analgesics 
and the major part of their analgesic and unwanted side-effects. 
1.2.1  Structure, anatomical localization and function of the µ-opioid recep-
tor 
The µ-opioid receptor belongs to the superfamily of G-protein-coupled receptors (GPCRs) and 
the subfamily of rhodopsin receptors. The structure of the receptor includes seven transmem-
brane domains, an extracellular N-terminus with multiple glycosylation sites, third intracellular 
loop with multiple amphiphatic α-helices, and fourth intracellular loop formed by the putative 
palmitoylation sites at the carboxyl tails. They are prototypical “Gi/Go-coupled” receptors be-
cause receptor signaling can be blocked by pertussis toxin (PTX), a bacterial toxin produced by 
Bordetella pertussis that inactivates the α-subunit of Gi/Go proteins (Gαi/o subunits) [18].  
The anatomical localization of the μ-opioid receptors is consistent with known pathways re-
lated to nociceptive signaling. They are expressed on peripheral nociceptors after inflamma-
tion, on spinal cord dorsal horn neurons and on neurons of the various brain regions involved 
in pain processing. In the spinal cord, μ-opioid receptors are expressed on primary afferent 
nociceptors that terminate
 in lamina I and II of the dorsal horn and on glutamatergic interneu-
rons
 in lamina II [19]. Cortical and subcortical areas expressing μ-opioid receptors include pri-
mary and secondary somatosensory cortices SI and SII, the insula, the anterior cingulate cortex 
and midcingulate cortex, the striatum, nucleus accumbens, septal nuclei, islands of Calleja, 
hippocampal regions, amygdaloid nuclei, several thalamic nuclei, habenular nuclei, interpe-
duncular nuclei, several raphe nuclei (e.g. nucleus raphe magnus), colliculi, parabrachial nuclei, 
locus coeruleus, nucleus ambiguous, nuclei of the sensory trigeminal complex and nucleus of 
the solitary tract [20, 21]. In contrast, the occipital lobe of the brain is known to be absent of µ-
opioid receptors [22]. 
Activation of µ-opioid receptors results in an inhibition of adenylyl cyclases (AC) and calcium 
(Ca
2+) channels (Figure 2). It further results in a stimulation of potassium (K
+) channels, phos-
pholipase C and MAP-Kinase. Activation of μ-opioid receptors on pre-synaptic neurons results 팠˝
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in a decrease of the calcium ion (Ca
2+) influx, which leads to a reduction of neurotransmitter 
release, e.g. the release of Substance P, into the synaptic gap. On the post-synaptic side, acti-
vation of μ-opioid receptors enhances the potassium ion (K
+) efflux resulting in a hyperpolari-
sation of postsynaptic neurons. Thus, activation of pre- and post-synaptic μ-opioid receptors 
on spinal cord dorsal horn neurons leads to a decrease of synaptic nociceptive transmission. In 
the brainstem, activation of μ-opioid receptors results in the excitation of the descending pain 
inhibitory system by a disinhibition of GABAergic neurons that inhibit pain-inhibitory neurons. 
In contrast to the immediate effects on pain transmission, alterations of cAMP levels are asso-
ciated with cellular changes that lead to the development of tolerance and physical depen-
dence [23]. Taken together, the activation of µ-opioid receptors leads to a decrease of the 
release of excitatory neurotransmitters from pre-synaptic neurons into the synaptic cleft and 
to a hyperpolarisation of post-synaptic neurons, finally resulting in a reduced excitability of 
nociceptive pathways and brain regions involved in pain perception. 
Figure 2: Intracellular effects after activation of µ-opioid receptors. Binding of µ-opioid receptor agon-
ists (e.g. morphine) results G-protein mediated in the following intracellular effects: i, inhibition of the 
adenylylcyclase, ii, inhibition of voltage dependent calcium channels, iii, activation of inward rectifying 
potassium channels, iv, activation of phospholipase C and v, activation of MAP-Kinase.  
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1.2.2  Pharmacological effects of opioid analgesics 
The effectiveness of opioid analgesics in pain treatment is based on their interaction with μ-
opioid receptors interrupting nociceptive signaling on nearly every level of pain transmission 
and pain perception. However, since the receptors are expressed in the whole body and not 
only in pain processing brain regions, activation of the receptor triggers not only analgesia but 
also numerous unwanted effects such as sedation, nausea and vomiting, constipation and res-
piratory depression, confusion, hallucinations, nightmares, urinary retention, miosis, multifocal 
myoclonus, dizziness, dysphoria and hyperalgesia [24]. For example, constipation is triggered 
by µ-opioid receptor activation in the gastrointestinal tract, and anatomical and in vitro studies 
suggest that µ-opioid receptors on pre-Bötzinger complex neurons are responsible for opioid 
induced respiratory depression [25]. 
Respiratory depression is the most life-threatening unwanted effect that occurs during opioid 
treatment and that patients die due to an opioid treatment is nearly always because of respi-
ratory rest. Even under controlled clinical conditions opioid administration can result in fatal 
respiratory depression [26-30]. Thus, opioid treated subjects must be under tight medical su-
pervision including measurements of their blood oxygenation level and, under critical condi-
tions, the respiratory depression must be reversed by administration of the specific opioid 
antagonist naloxone.  
1.2.3  Mu-opioid receptor coding gene OPRM1  
The magnitude of opioid effects is subject to a large inter-individual variability. They depend 
on factors like age, organ dysfunctions, extent of disease, concurrent administration of certain 
drugs, prior opioid exposure and the route of drug administration [24]. In addition, advances in 
genetic research revealed that there is also a genetic component involved. 
Besides genetic variations affecting the pharmacokinetics of opioid analgesics, genetic varia-
tions affecting their primary target structure, the µ-opioid receptor, are primary candidates for 
investigations  regarding  the  inter-individual  variability  of  opioid  effects.  The  OPRM1  gene 
codes for  -opioid receptors [31, 32]. It is located on chromosome 6q24-q25 (Figure 3). Several 
mutations in the promoter, exons (coding regions) and introns (non-coding regions) of the 
OPRM1 gene have been identified [33, 34]. The mutations cause amino acid exchanges in the 
receptor protein or alternative splicing, thus, possibly affecting receptor function or receptor 
expression. Four single nucleotide polymorphisms of the OPRM1 gene have been shown to 팠Х
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alter agonist binding or impair receptor signaling: The OPRM1 118A>G single-nucleotide poly-
morphism (SNP) in exon 1, which affects the extracellular binding domain of the μ-opioid re-
ceptor, as well as SNP 779G>A, SNP 794G>A and SNP 802 T>C in exon 3, which affect the third 
intracellular loop of the μ-opioid receptor [35].  
The 118A>G single-nucleotide polymorphism (SNP) in exon 1 of the OPRM1 gene emerges as 
one of the most interesting mutations [36]. It causes an amino acid exchange at position 40 of 
the μ-opioid receptor protein from asparagines (Asn; N) to aspartate (Asp; D) (N40D), deleting 
a putative N-glycosylation site in the extracellular receptor region. Due to its allelic frequency 
of 17.2 % (according to the dbSNP database at http://www.ncbi.nlm.nih.gov/SNP/; SNP ref-
erence ID rs1799971), a change in receptor functionality would imply immediate clinical relev-
ance for the administration of opioids in a larger part of the population. In contrast, SNP 
779G>A, SNP 794G>A and SNP 802 T>C are not of immediate clinical importance because of 
their low reported allelic frequency (<<1%). 
Figure 3: Location of the most common SNPs of the OPRM1 gene and their respective location in the 
µ-opioid receptor protein. SNPs with reported functional consequences (red) are the OPRM1 118A>G 
(N40D) and 779G>A (R260H), 794G>A (R265H) and 802T>C (S268P; [35]).  
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1.2.4  Mu-opioid receptor gene variant OPRM1 118A>G  
The earliest report regarding SNP OPRM1 118A>G as a µ-opioid receptor gene variant with 
functional consequences stated that N40D variant μ-opioid receptors expressed in Syrian ham-
ster adenovirus-12-induced tumor cells (AV-12) had, in contrast to other opioids like morphine 
and M6G, a 3-fold higher binding affinity to its endogenous ligand β-endorphine compared to 
wildtype receptors [37]. Furthermore, β-endorphine was more potent in activation of the G-
protein activated inwardly rectifying potassium (K
+) channel (GIRK) in Xenopus oocytes ex-
pressing the variant receptors. Contrary to this publication, two succeeding studies demon-
strated that μ-opioid receptor binding affinity to opioid agonists including β-endorphine and, 
in addition, μ-opioid receptor signaling, measured by [
35S]-GTPγS binding and cAMP accumula-
tion, was unaffected in μ-opioid receptor mutant N40D expressing Cercopithecus aethiops 
cells (COS) [38] and human 293 embryonic kidney cells (HEK 293) [39]. Most recently, a 2-fold 
increase of the potency of DAMGO and morphine to activate N-type Ca
2+ channels in rat supe-
rior ganglion neurons transfected with OPRM1 118G cDNA has been shown [40].  
In addition, µ-opioid receptor density decreasing effects of OPRM1 variant 118G had been 
suggested, based on [
3H]-DAMGO saturation binding experiments in HEK 293-cells transfected 
with μ-opioid receptor mutant N40D. However, OPRM1 variant 118G has no effects on µ-
opioid receptor endocytosis and desensitization [39]. In agreement with this result, a recent 
publication demonstrated reduced mRNA expression of the 118G allele in human autopsy 
brain tissues of pons and cortical lobes of eight heterozygous carriers. In addition, the authors 
demonstrated a 1.5-fold lower mRNA level and 10-fold lower μ-opioid receptor expression in 
Chinese hamster ovary cells (CHO) transfected with OPRM1 118G cDNA. Since the mRNA sta-
bility was unaffected by the polymorphism, the authors suggested that this is due to a defect 
of transcription or mRNA maturation [41].  
In vivo, OPRM1 variant 118G has repeatedly been associated with decreased opioid analgesia. 
Patients treated because of postoperative pain with alfentanil or morphine needed 1.3-fold 
and 2-fold higher concentrations, respectively, to  achieve adequate analgesia [42-44]. Fur-
thermore, a 3-fold reduction of the analgesic potency of M6G in healthy carriers of OPRM1 
variant 118G treated with experimental pain has been reported [45, 46]. 
Similar to the analgesic effects of opioids, the miotic effects of morphine [47], morphine-6-
glucuronide [47, 48] and levomethadone [49] were decreased in carriers of the variant OPRM1 
118G allele. Furthermore, carriers of OPRM1 variant 118G vomited less frequently after high ِ 歐
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M6G doses [47] and good tolerance of high plasma M6G concentrations by a homozygous 
carrier of the 118G allele has been reported [50]. To this sharply contrasts a report of similar 
respiratory depression despite lower analgesia produced by M6G in four heterozygous carriers 
of the 118G allele as compared to 12 non-carriers [46], without including homozygous carriers. 
In addition, OPRM1 118A>G has been associated with vulnerability to substance abuse [51-53] 
and an increase of the cortisol response to mu-opioid receptor blockade with naloxone in ho-
mozygous carriers of mu-opioid receptor variant N40D [54, 55]. 
1.3  Aim of the study 
Taken together, despite the clear functional consequences of OPRM1 variant 118G for opioid 
analgesia and opioid side-effects, the molecular mechanism by which the variant causes the 
decrease in clinical opioid effects is currently unclear. Investigations using µ-opioid receptor 
transfected cell lines produced conflicting results and although a reduction of µ-opioid recep-
tor binding sites in carriers of OPRM1 variant 118G has been reported, the importance of the 
investigated brain regions for nociceptive transmission and pain perception is unknown. In 
addition, the consequences of the 118G allele for the drug safety and the therapeutic range of 
opioid analgesics are currently unclear but of immediate importance for clinical pain therapy 
with opioid analgesics. If the variant affects only opioid analgesia but leaves respiratory de-
pression unchanged, the advice of increased dosing to achieve adequate analgesia in 118G 
carriers would be dangerous. On the other hand, if both analgesia and respiratory depression 
were affected, increasing the opioid dose would be safe. 
The aim of the study was to identify the mechanism by which the OPRM1 118A>G SNP dimin-
ishes opioid effects and to explore its consequences for opioid effects in carriers of this variant. 
To achieve this, following step-wise approach was taken: In the first step, OPRM1 118A>G SNP 
affected brain regions of healthy homozygous 118G variant carriers were identified by observ-
ing variations of the response to opioid analgesics after painful stimulation using functional 
magnetic resonance imaging (fMRI). Afterwards, samples of brain regions displaying variations 
of the response to opioid analgesics were collected post mortem and the molecular mechan-
ism  underlying  the  variations  was  investigated.  Finally,  the  consequences  of  the  OPRM1 
118A>G SNP for the analgesic and respiratory depressive effects of opioids were quantified in 
healthy carriers and non-carriers of the OPRM1 118A>G SNP and it was analyzed whether the 
therapeutic range of opioid analgesics is altered in carriers of this variant.  ّ
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2  Material and Methods 
2.1  Enrolment of healthy subjects 
The participants of the clinical studies were mostly medical students recruited via flyers distri-
buted at the campus of the University of Frankfurt. During recruitment, subjects were given 
detailed  information  about  the  testing  procedures  and  written  informed  consent  was  ob-
tained. The subjects´ current health was ascertained by medical examination and routine la-
boratory analyses. Exclusion criteria were drug addiction, any chronic disease, the use of any 
medications except for anticonceptionals within the last week before the actual experiments, 
pregnancy and lactation. A total number of 740 unrelated volunteers of Caucasian ethnicity, 
who had consented into genotyping, were screened for the OPRM1 118A>G single nucleotide 
polymorphism.  
2.2  Collection of human brain tissue 
Human brain tissue was sampled during autopsy at the Institute of Forensic Medicine and the 
Senckenberg Institute for Pathology of the Johann Wolfgang Goethe-University of Frankfurt 
am Main, Germany. Tissue was collected from a total number of 95 subjects. The included 
subjects neither received an opioid treatment nor had a known history of drug addiction. The 
collected tissue included the secondary somatosensory cortex SII and the ventral posterior part 
of the lateral thalamus. Tissue samples were stored at – 80°C pending further analysis. 
2.3  Genetic screening for carriers of SNP OPRM1 118A>G 
For genotyping of the healthy subjects and post mortem brain samples, genomic deoxyribo-
nucleic acid (DNA) was extracted from either heparinized blood samples (10 ml) using the EZ1 
DNA Blood 200 μl Kit or from brain tissue (10 mg) using the EZ1 DNA Tissue Kit on a BioRobot 
EZ1 Workstation (Qiagen, Hilden, Germany). Subsequently, an OPRM1 DNA segment of 393 
nucleotides including position 118 was amplified by using the following primers: biotinylated 
forward primer 5´-CTC CGC CTG ACG CTC C-3´ with reverse primer: 5´-GTA GAG GGC CAT GAT 
CGT GAT-3´. The polymerase chain reaction (PCR) was performed by use of 5 μl genomic DNA 
(20-30 μg/ml) mixed with 0.5 μl Hotmaster Taq (Thermus aquaticus; Eppendorf, Hamburg, 
Germany) DNA polymerase, 1 μl of 10 mM deoxynucleotide triphosphate mix (Roche, Penz-
berg, Germany), 0.1 μl of each PCR primer (100 μM), 5 μl concentrated (10*) PCR reaction buf- ّ
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fer without magnesium chloride and 38.3 μl HPLC-purified water (J.T. Baker, Deventer, The 
Netherlands). The thermal cycler protocol was set at 40 cycles and used an initial denaturation 
step at 95°C for 5 minutes, with amplification at 95°C for 30 seconds, followed by annealing at 
primer-specific temperatures (55.5°C) for 60 seconds, 30 seconds of elongation at 72°C, and 
cooling down to 4°C.  
Genetic polymorphisms were detected by use of validated Pyrosequencing [56] assays on a 
PSQ 96MA device (Biotage, Uppsala, Sweden; Figure 4). Samples with known sequences at the 
respective SNP positions (previously obtained by classic sequencing) were included in each 
analysis as quality control. A small volume of 25 μl of the PCR-template was transferred into a 
single well of a microtest plate U96 (Ratiolab GmbH, Dreieich, Germany) containing a mixture 
of 3 μl streptavidin-coated sepharose beads (Amersham Pharmacia Biotech, Uppsala, Sweden), 
37 μl Binding-buffer (Biotage, Uppsala, Sweden) and 15 μl purified H2O. Subsequently, the 
mixture was incubated for 10 min at room temperature while shaking. The template was fur-
ther treated according to the pyrosequencing protocol with Ethanol 70%, 0.2M NaOH and 
10mM Tris Acetate buffer before it was transferred into a PSQ 96 Plate Low (Pyrosequencing 
AB, Uppsala, Sweden), containing 0.35 μM of sequencing primer and 40 μl of Annealing-Buffer 
(Biotage, Uppsala, Sweden). The mixture of template and sequencing primer was incubated for 
60 seconds at 80°C and then transferred to the PSQ 96MA device. Genotyping for OPRM1 mu-
tation 118A>G was performed with sequencing primer 5´-TGG GTC GGA CAG GT-3´.  
From the 740 healthy subjects, 588 were non-carriers, 136 were heterozygous and 16 were 
homozygous carriers of the variant OPRM1 118G allele. The allelic frequency of the variant 
118G allele in this random sample was 11.4%. The 95 samples of post mortem human brain 
tissue included 68 non-carriers, 24 heterozygous and three homozygous carriers of the variant 
OPRM1 118G allele. The allelic frequency of the variant 118G allele in this random sample was 
15.8%. Both samples corresponded to the Hardy-Weinberg equilibrium [57] (Chi
2-test: p=0.89) 
indicating a random sample of subjects with respect to 118A>G. 
    ّ
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Figure 4: Pyrosequencing. Left side: Principle of Pyrosequencing according to manufacturer Biotage 
(http://www.pyrosequencing.com/DynPage.aspx?id=7454). A sequencing primer is hybridized to a sin-
gle stranded, PCR amplified DNA template, and incubated with the enzymes, DNA polymerase, ATP 
sulfurylase, luciferase and apyrase, and the substrates, adenosine 5´ phosphosulfate (APS) and luciferin. 
The first of four deoxynucleotide triphosphates (dNTP) is added to the reaction. DNA polymerase cata-
lyzes the incorporation of the deoxynucleotide triphosphate into the DNA strand, if it is complementary 
to the base in the template strand. Each incorporation event is accompanied by release of pyrophos-
phate (PPi) in a quantity equimolar to the amount of incorporated nucleotide. ATP sulfurylase quantita-
tively converts PPi to ATP in the presence of adenosine 5´ phosphosulfate. This ATP drives the luciferase-
mediated conversion of luciferin to oxyluciferin that generates visible light in amounts that are propor-
tional to the amount of ATP. The light produced in the luciferase-catalyzed reaction is detected by a 
charge coupled device (CCD) camera and seen as a peak in a pyrogram™. Each light signal is proportional 
to the number of nucleotides incorporated. Apyrase, a nucleotide degrading enzyme, continuously de-
grades unincorporated dNTPs and excess ATP. When degradation is complete, another dNTP is added. 
Addition of dNTPs is performed one at a time. As the process continues, the complementary DNA strand 
is built up and the nucleotide sequence is determined from the signal peak in the pyrogram. Right side: 
Appropriate pyrograms™ of non-carriers, hetero- and homozygous carriers of OPRM1 variant 118G. 
  ٚ
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2.4  Study designs 
All study protocols were in accordance with the Helsinki Declaration of Biomedical Research 
Involving Human Subjects and were approved by the Medical Faculty Ethics Review Board of 
the Johann Wolfgang Goethe-University of Frankfurt. 
All trials were performed without a placebo condition because (i) previous experiments in the 
laboratory did not suggest a temporal bias of the pharmacodynamic target parameters of the 
studies, (ii) we wanted to compare differences among genotypes, so that a possible placebo 
effect should have affected both genotypes in a similar manner and not compromised their 
comparability, and (iii) opioid administration is usually noticed by both the subjects and the 
observers when compared with saline administration, thus compromising the blinding, and an 
established active placebo is not available. 
2.4.1  Investigation of pain-related brain activation during alfentanil admin-
istration in non-carriers and homozygous carriers of OPRM1 118A>G 
SNP 
In this study, OPRM1 118A>G SNP affected brain regions of healthy homozygous 118G variant 
carriers were identified by observing variations of the response to opioid analgesics after pain-
ful stimulation using functional magnetic resonance imaging (fMRI).  
This study was a single-occasion open-label design. Experiments included one pain model, the 
gaseous CO2 pain model (2.5.3.2). All subjects received a computer-controlled intravenous 
infusion of alfentanil (2.5.1) to establish four predefined different levels of plasma concentra-
tions, which were 0 ng/ml at baseline (level 0) and, according to liquid chromatographic tan-
dem mass spectrometric (LC-MS/MS) determination, 19.6±2.7 (level 1), 47.2±7.6 (level 2) and 
76.6±11.3 ng/ml (level 3). We allowed 5 minutes equilibration time for each concentration 
level before the brain activation by the pain stimuli was quantified by means of functional 
magnetic resonance imaging (fMRI; 2.5.3.2.3). At each alfentanil concentration level, 24 specif-
ic nociceptive stimuli, consisting of short (300 ms) pulses of gaseous carbon dioxide (CO2; 66% 
v/v) were delivered to the nasal mucosa of the right nostril. To avoid adaptation and habitua-
tion to the pain stimuli, an interstimulus interval of 26 sec was used [58]. Concomitantly, we 
recorded the changes in the blood-oxygenation level dependent (BOLD) response to these 
specific nociceptive stimuli by means of fMRI, employing an event-related design (2.5.3.2.3). 
Subsequent to recordings at concentration level 3, the alfentanil infusion was stopped and  ّ
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after a break of 20 minutes, during which the participant remained in the scanner, an addi-
tional measurement was performed to explore reversal of opioid effects (level 4; 47.8 ± 9.0 
ng/ml). Following completion of the experiment, ratings of the mean pain intensity at each 
opioid concentration level were obtained by a visual analogue scale (length 100 mm, ranging 
from “no pain” to “pain experienced at maximum”). This post-hoc intensity estimation avoided 
confounding the pain-related brain activation by the activation associated with the rating task 
[59]. The actual experiments were performed between 9 a.m. and 2 p.m. The subjects´ breath-
ing rate, heart rate and blood oxygenation were constantly monitored to exclude opioid in-
duced changes of the haemodynamic response function (HRF). Since blood oxygenation was 
never below 98%, an influence of opioids on the HRF can be excluded. At a separate day prior 
to the study occasion, subjects underwent a training session in the MRI scanner that corres-
ponded to a complete measurement at level 0. 
A total number of 16 non-addicted healthy homozygous carriers of the OPRM1 variant 118A 
(eight men, eight women, mean age 27.8±4.8 years, mean body weight 69.1±12.6 kg) and nine 
homozygous carriers of the OPRM1 variant 118G (four men, five women, mean age 27.5±4.1 
years, mean body weight 71.3±18.7 kg) were included into the study. All participants were 
unaware of their individual genotype. Subjects were right-handed except for one. The groups 
(118AA,  118GG)  did  not  differ  significantly  with  respect  to  gender  distribution,  age,  body 
weight, and measured alfentanil concentrations at levels 0 to 3 (Wilcoxon tests: p>0.13). 
2.4.2  Investigation of µ-opioid receptor expression and function in pain 
processing brain regions of non-carriers and carriers of OPRM1 
118A>G SNP 
The molecular mechanism underlying the in vivo observations that the SNP OPRM1 118A>G 
alters opioid effects in pain processing brain regions was investigated in human brain samples 
collected post mortem. Based on the fMRI findings, the collected tissues included a brain re-
gion shown to be affected by the SNP OPRM1 118A>G, namely the SII-region, a cortical region 
that is associated with processing the sensory information of pain [7]. On the other hand, a 
brain  region was  collected  that  was  unaffected  by  the  SNP  OPRM1 118A>G,  but  which  is 
known to be important for the pain processing and to express µ-opioid receptors, namely the 
ventral posterior part of the lateral thalamus, a sub-cortical region that is known to route affe-
rent nociceptive signals to the somatosensory cortices SI and SII [5].  ّ
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OPRM1 mRNA expression analysis was performed by means of real-time PCR analysis (see 
chapter  2.6.1).  Furthermore,  saturation  binding-experiments  (see  chapter  2.6.4)  were  per-
formed with the μ-opioid receptor specific ligand [
3H]-DAMGO (
3H-[D-Ala
2,N-MePhe
4,Gly-ol
5]-
enkephalin) to investigate µ-opioid receptor density and µ-opioid receptor affinity in both 
brain regions. In addition, [
3H]-DAMGO displacement binding experiments were performed 
with samples of the SII-region to determine the affinity of the endogenous, predominantly µ-
opioid receptor binding neurotransmitter β-endorphine and to determine the affinity of com-
monly used opioid analgesics (morphine, methadone and alfentanil) and their metabolites 
(M6G). Last but not least, the ability of the µ-opioid receptor to activate the intracellular G-
protein after binding of DAMGO was studied by means of [
35S]-GTPγS binding assays (see chap-
ter 2.6.5).  
Brain tissue samples were analyzed from all three homozygous subjects and from 21 hetero-
zygous carriers. For analysis of non-carriers, a random sample of n=22 was taken to match the 
heterozygous carriers (for subject related data see Table 1). However, because of limited tis-
sue availability it was not possible to employ every subject in all experiments. The exact sam-
ple sizes are indicated at the respective results. OPRM1 genotype groups did not differ with 
respect to sex, age at death, post mortem delay and tissue storage period (analyses of va-
riance: not significant). 
 
    ّ
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Table 1: Information about the genotype, sex, age at death, post mortem delay until sample extrac-
tion, storage time and cause of death of each subject included into the analysis. 
Subject 
OPRM1  
118 
Sex 
 [m/f] 
Age at death 
[yrs] 
pm delay 
[h] 
Storage 
time 
[months]  Cause of death 
1  AA  m  67  12  29  Pulmonary embolism 
2  AA  m  58  24  28  Myocardial infarction 
3  GG  f  42  48  28  Respiratory failure 
4  AG  f  66  10  28  Myocardial infarction 
5  AA  m  73  48  28  Aspergillus pneumonia 
6  AG  m  89  36  28  Pneumonia 
7  AA  f  59  48  28  Myocardial infarction 
8  AG  m  68  48  28  Myocardial infarction 
9  AA  f  77  6  25  Cardiac failure 
10  AA  m  64  72  25  Myocardial infarction 
11  AA  m  65  48  25  Endocarditis 
12  AA  f  80  24  24  Mamma carc. (no therapy) 
13  AG  m  62  9  24  Myocardial infarction 
14  AG  m  62  24  23  Renal failure 
15  AG  m  73  7  23  Myocardial infarction 
16  AA  f  56  7  23  Liver failure 
17  AA  f  53  12  23  Respiratory failure 
18  AA  m  74  24  23  Myocardial infarction 
19  AA  m  63  12  23  Hemorrhagic shock 
20  AG  f  91  12  23  Hemorrhagic shock 
21  AA  m  87  24  22  Hemorrhagic shock 
22  AG  m  81  24  22  Myocardial infarction 
23  AG  f  51  72  20  Liver failure 
24  AG  m  70  8  19  Myocardial infarction 
25  AA  m  28  23  17  Hemorrhagic shock 
26  AA  m  25  85  16  Sepsis 
27  AG  f  39  85  16  Respiratory failure 
28  AG  m  47  19  16  Intoxication 
29  AA  f  42  20  15  Hemorrhagic shock 
30  AA  f  20  19  15  Hemorrhagic shock 
31  AG  m  65  24  14  Hemorrhagic shock 
32  AA  f  49  4  15  Homicide 
33  AA  f  19  26  14  Pulmonary embolism 
34  AG  m  47  47  14  Myocardial infarction 
35  AA  f  84  46  14  Hemorrhagic shock 
36  AA  m  49  28  14  Cardiac failure 
37  AG  m  50  67  14  Hemorrhagic shock 
38  AG  f  92  0  14  Cardiac failure 
39  AG  m  71  67  14  Hemorrhagic shock 
40  AG  f  39  29  13  Cardiac failure 
41  AG  f  34  15  11  Hemorrhagic shock 
42  AG  f  41  11  11  Hemorrhagic shock 
43  AG  f  38  48  11  Hemorrhagic shock 
44  AA  f  71  39  9.9  Myocardial infarction 
45  GG  f  23  17  9  Multiple organ failure 
46  GG  f  68  22  9  Heart failure 
  Mean ± SD  23m/23f  58.1 ± 19.5  30.4 ± 22.2  19.3 ± 6.2    ٖ
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2.4.3  Investigation of the therapeutic range of alfentanil in non-carriers and 
carriers of OPRM1 118A>G SNP 
This study investigated the consequences of the OPRM1 118A>G SNP for the analgesic and 
respiratory depressive effects of opioids. Furthermore, it was analyzed whether the therapeu-
tic range of opioid analgesics is altered in carriers this variant.  
The study was a single-occasion open-label design. Experiments included two pain models, 
namely the transcutaneous electrical pain stimulation (2.5.3.1) and the short (200 ms) pulses 
of gaseous CO2 (65% v/v) applied to the nasal mucosa (2.5.3.2). In addition, experiments in-
cluded two methods for the quantification of respiratory depression, namely the hypercapnic 
challenge  test  according  to  Read  (2.5.4.1)  and  monitoring  of  the  spontaneous  breathing 
(2.5.4.2). Experiments started with assessment of baseline values of respiratory depression 
and analgesia (Level 1). Measurements were always exhibited in the same order, as following: 
transcutaneous electrical stimulation, CO2 re-breathing, CO2 pain stimulation (20 CO2 stimuli, 
inter-stimulus interval 20 sec) and assessment of the respiratory frequency. After assessment 
of baseline values, an intravenous line was inserted into each forearm for drug administration 
and for blood sampling. The participants received in an open-label fashion an intravenous infu-
sion of alfentanil hydrochloride (2.5.1). Three different alfentanil target concentrations at ef-
fect site (Level 2-4) were employed by means of a computerized infusion. The study began 
with a target alfentanil concentration at effect site of 33.33 ng/ml for 65 minutes. After an 
equilibration period of 15 min, which was found by PK/PD simulations to be sufficient for com-
plete equilibration between plasma and effect site, all experiments were performed again 
within the remaining 50 min (Level 2) before switching to the next higher concentration. This 
procedure was repeated twice with higher target alfentanil concentrations at effect site of 
66.67 ng/ml (Level 3) and 100 ng/ml (Level 4). In the beginning (15
th min), in the middle (40
th 
min) and at the end of each Level (65
th min), a venous blood sample was collected to a Na-
EDTA tube for analysis of alfentanil plasma concentrations. The blood samples were kept on 
ice until the end of the study day and were then immediately centrifuged at 3,000 rpm for 10 
min. The plasma was frozen at -78°C pending further analysis. During the study day partici-
pants were rested in a comfortable position and the subjects were under constant medical 
supervision. Medical symptoms reported by the subjects and the occurrence of vomiting were 
recorded (2.5.5). Intake of alcoholic beverages was prohibited for 24 h and intake of food for 6 
h prior to experiments. The subjects were under continuous medical supervision throughout  ّ
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the study day. Heart rate, respiration frequency and blood oxygenation were monitored using 
a pulseoxymeter. The subjects remained at the laboratory for at least another 2 hours after 
the end of infusion. All subjects completed a training session prior to the actual study occasion. 
The aim of the study was to assess the consequences of the OPRM1 118G allele for the thera-
peutic range of alfentanil, rather than to establish a gene dose effect. A group size of six was 
obtained by case number calculations based on previous data [60] and on a statistical power of 
0.8. For safety, the group size was defined at 10. Since we did not find more than six homozyg-
ous carriers of the variant 118G allele who consented into participation in the study, we re-
cruited four heterozygous carriers to match the recruited ten controls. The study population 
was then separated into three genetic groups (118AA, 118AG, 118GG). The 118AA group con-
sisted of homozygous carriers of the 118AA allele (five women, five men, mean age = 28.8 
years, mean BMI = 22.0), the 118AG group (three women, one man, mean age = 24.0 years, 
mean BMI = 21.3) consisted of heterozygous carriers and the 118GG group (two women, four 
men, mean age = 28.4 years, mean BMI = 26.1) consisted of homozygous carriers of the 118GG 
allele variant (Proportion of female/male between groups: Fishers exact test p=0.63; BMI: 
Kruskal-Wallis test (AA vs. AG vs. GG) p=0.39, Wilcoxon test (AA vs. AG/GG) p=0.31). All sub-
jects were unaware of their OPRM1 genotype. 
2.5  Assessment of opioid effects in healthy humans 
2.5.1  Administration of alfentanil by computerized infusion 
In both clinical trials described in this thesis, the participants received in an open-label fashion 
an intravenous infusion of alfentanil hydrochloride (Rapifen
®, JANSSEN-CILAG GmbH, Neuss, 
Germany). Alfentanil was chosen because of its fast equilibration between plasma and effect 
site, the central nervous system (CNS), which allows to consider the plasma concentrations as 
being similar to the brain concentrations after 5 min equilibration time (t1/2,ke0(Alfentanil) = 0.6-1.2 
minutes; [61]). In addition, the fast equilibration between plasma and brain and the short time 
of alfentanil action allowed for keeping the duration of the experiments short and ensured 
quick recovery of the subjects from the opioid effects after the end of the alfentanil infusion. 
To maintain a constant alfentanil concentration at the effects site, alfentanil was administered 
by means of computerized infusion using STANPUMP program ([62] freely available from Ste-
ven  L.  Shafer,  MD  at  http://anesthesia.stanford.edu/pkpd)  with  Scott’s  pharmacokinetic  ّ
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parameters for alfentanil (weight adjusted; [61]) and the Harvard pump 22 (Instech Laborato-
ries, Plymouth Meeting, PA, USA).  
2.5.2  Analysis of alfentanil plasma concentrations 
To assure that all subjects received similar treatment, drug plasma concentrations were de-
termined  by means of  liquid  chromatographic  tandem  mass spectrometric  (LC-MS/MS).  In 
addition,  analysis  of  the  drug  plasma  concentrations  allowed  for  pharmacokinetic-
pharmacodynamic modelling (PK-PD modelling, chapter 2.7.3). Therefore, venous blood sam-
ples (4 ml) were collected into Na-EDTA tube at predefined time points. After centrifugation at 
4000 min
-1 for 10 min, plasma was separated and deep frozen at -78°C pending further analy-
sis. Alfentanil (Janssen-Cilag, Neuss, Germany) was extracted by protein precipitation using 
fentanyl (Janssen-Cilag, Neuss, Germany) as internal standard. Therefore, 20 µl human plasma 
was thoroughly mixed with 20 µl fentanyl-solution (12 ng/ml in acetonitrile), 50 µl acetonitrile 
and 200 µl methanol. Calibration standards were prepared in the same manner with blank 
human plasma (Blutspendedienst Hessen, Frankfurt am Main, Germany), but instead of 50 µl 
acetonitrile, 50 µl of standard solution in acetonitrile was used. The samples were centrifuged 
for 5 min at 10,000 g and 20 µl of the supernatant was diluted with 200 µl acetonitrile/formic 
acid (100:0.25, v/v). After another 5 min of centrifugation at 10,000 g, 100 µl of the solution 
was transferred to glass vials (Macherey-Nagel, Düren, Germany) prior to injection into the LC-
MS/MS system. The LC-MS/MS system consisted of an API 4000 triple-mass spectrometer (Ap-
plied Biosystems, Darmstadt, Germany) equipped with a Turbo-V-source operating in positive 
ESI mode, an Agilent 1100 binary HPLC pump and degasser (Agilent, Böblingen, Germany) and 
a HTC Pal autosampler (Chromtech, Idstein). For the chromatographic separation an Alltima HP 
HILIC column and precolumn were used (50 x 2.1 mm I.D., 3 µm particle size from Alltech, Un-
terhaching, Germany). Mobile phase was acetonitrile/water/formic acid (90:10:0.25, v/v/v), 
flow rate was 700 µl/min and total run time 2.5 min. Injection volume of samples was 20 µl. 
Retention  time of  alfentanil  and  fentanyl  was  1.16  min  and  1.03 min,  respectively.  HPLC-
solvents were of HPLC-quality (Merck KgaA, Darmstadt, Germany). Multiple reaction monitor-
ing (MRM) was used for quantification. The mass transitions used were m/z 417 → m/z 268 
for alfentanil and m/z 337 → m/z 188 for fentanyl. Quantitation was performed with Analyst 
Software V1.4 (Applied Biosystems, Darmstadt, Germany) using the internal standard method 
(isotope-dilution mass spectrometry): Ratios of alfentanil and fentanyl peak area were plotted 
against concentration. Lower limit of quantification of alfentanil was 0.1 ng/ml (14 fg on col- ّ
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umn). Accuracy of the method over the calibration range (0.1 to 500 ng/ml) was 100.01 ± 5.98 
% (n = 8). 
2.5.3  Assessment of pain 
2.5.3.1  Transcutaneous electrical stimulation 
2.5.3.1.1 Procedure 
Short electrical stimuli (2 sec) of increasing intensity were applied to the subjects´ left forefin-
ger. Therefore a constant current device (NEUROMETER CPT, Neurotron Inc., Baltimore, MD, 
USA) with a maximum output of 20 mA was used to administer painful electrical 5Hz sine wave 
pulses via two gold electrodes placed on the medial and lateral side of the distal phalangeal 
joint (middle finger of the left hand as default-testing site). The electrical stimulus has been 
shown to primarily activate C-fibers (Kiso et al. 2001; Lötsch and Angst 2003). 
2.5.3.1.2 Psychophysical quantification of pain and analgesia 
To assess each individuals pain tolerance threshold after electrical stimulation, i.e. the electric-
al current when the subjects pain experience changes from tolerable to intolerable, the stimu-
lation started with an electrical current known not to be painful, whereas stimulus intensity 
varied randomly between 1.2 mA and 2.8 mA. The current was then further increased in an 
ascending staircase design until the subjects reported to feel pain (Figure 5). The magnitude of 
subsequent stimuli was determined by the subject’s response to the two preceding stimuli. If a 
subject’s response to two preceding stimuli was “no pain – no pain” or “pain – pain” the next 
stimulus was equal to the magnitude of the last delivered stimulus plus or minus 130% of the 
difference between the last and the second last stimulus, respectively. If a subject’s response 
to two preceding stimuli was “no pain – pain” or “pain – no pain” the next stimulus was equal 
to the magnitude of the second last stimulus plus 75 or 25% of the difference between the last 
and the second last stimulus, respectively. The purpose of the outlined algorithm was to in-
crease or decrease the magnitude of delivered stimuli quickly as long as a subject gave a uni-
form response, i.e., “no pain” or “pain”. Whenever a subject changed the response from “no 
pain” to “pain” or from “pain” to “no pain”, the outlined algorithm allowed the magnitude of 
stimuli evoking a change in response at a higher resolution. Subsequently, the pain threshold 
was obtained from 10 stimuli by logistic regression of “pain” or “no pain” (corresponding to 
“0” or “1”) versus the intensity of the electrical current. The interstimulus interval was approx-
imately 30-60 sec. After opioid administration an increase of the pain tolerance threshold is  ّ
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expected, indicating analgesic opioid effects. This pain model has been repeatedly demon-
strated to be suitable to quantify the analgesic effects of opioids such as hydromorphone [63], 
morphine [64], remifentanil [36], or alfentanil [65].  
Figure 5: Electrical pain model. The subjects received a 5 Hz sine waves pulses with a length of two 
seconds in the range from 0-20 mA intermitted by short breaks of approximately 30-60sec. The amount 
of the electrical current was increased until the subject described the stimulus as painful. Subsequently, 
the current is decreased until the subject describes the stimulus as non painful. Whenever a subject 
changes the response from “no pain” to “pain” or from “pain” to “no pain”, the outlined algorithm al-
lows the magnitude of stimuli evoking a change in response at a higher resolution. Subsequently, the 
pain threshold was obtained from a maximum of 10 stimuli by logistic regression of “pain” or “no pain” 
(corresponding to “0” or “1”) versus the intensity of the electrical current. 
 
 
2.5.3.2  Painful gaseous carbon dioxide stimuli applied to the nasal mucosa 
2.5.3.2.1 Procedure 
In this pain model, short pulses of gaseous carbon dioxide (CO2) were applied to the subjects´ 
nasal mucosa of the right nostril (Figure 6). A special device (Olfactometer OM/2, Burghart 
Instruments, Wedel, Germany) allows for precise control of the concentration and duration of 
the rectangular CO2 stimuli [66]. The CO2 pulses evokes pain with a stinging character and have 
been shown to excite trigeminal Aδ-fibers, with co-activation of trigeminal C-fibers [67] via a 
local pH decrease and stimulation of vanilloid receptors (TRPV1) [68] that are expressed in 
trigeminal sensory neurons projecting to the nasal mucosa. The nociceptive specificity of the 
chemical pain stimuli is supported by the localization of the cortical generators of the resulting 
Time
Pain tolerance threshold
Intolerable Pain
No Pain
A
m
p
e
r
a
g
e
}
ISI=30 60 sec
20
0
 20
A
m
p
e
r
a
g
e
 
(
m
A
)
Time (sec) 2
Tolerable Pain
20
0
 20
A
m
p
e
r
a
g
e
 
(
m
A
)
Time (sec) 2
20
0
 20
A
m
p
e
r
a
g
e
 
(
m
A
)
Time (sec) 2
Perception threshold ٖ
  Material and Methods   
 
23 
nociceptive event related potentials (ERPs) in the somatosensory area SII [69], which is consi-
dered to be a primary projection area for nociceptive afferents [7]. To maintain the nociceptive 
specificity of the CO2-stimuli, concomitant alteration of mechanical or thermal conditions at 
the  mucosa  is  avoided  by  embedding  the  CO2-pulses  in  a  constantly  flowing  air  stream 
(8 l/min) with controlled temperature and humidity (36.5°C, 80 % relative humidity). This car-
rier stream is led to the right nasal cavity via a thin Teflon tube with an outer diameter of 
1.5 mm. This pain model has repeatedly been demonstrated to reliably and sensitively quantify 
the analgesic effects of opioids such as fentanyl [70], alfentanil [65] or morphine [36]. 
Figure 6: CO2 pain model. Flow schema of the air stream between two CO2 stimuli (left side) and during 
application of a stimulus. 
 
 
2.5.3.2.2 Psychophysical quantification of pain and analgesia 
The painful CO2 pulses were rated by means of a visual analogue scale (VAS) ranging from zero 
(“no pain”) to 100 (“severe pain”). Prior to the experiment, subjects received 10 CO2 pulses of 
five different concentrations (46, 53, 65, 68, 73% v/v). Since the highest technical possible CO2 
concentration is still perceived as only moderate painful by the most subjects, subjects were 
told that they should rate the lowest concentration (46% v/v) as zero (“no pain”) and the high-
est concentrations (73% v/v) as 100 (“severe pain”). During the experiment, between two sti-
muli the subjects had to perform a tracking task on a video screen (Figure 7). Within 3-4 sec 
after the presentation of each CO2 stimulus, a visual analogue scale was displayed on the video 
screen and subjects estimated the pain intensity relative to the presented concentrations prior 
to the experiment. The visual analogue scale appeared as a horizontal bar without numbers. 
to 
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The length of this bar was manipulated by the subjects by means of a joystick. After opioid 
administration, an decrease of the ratings is expected indicating analgesic opioid effects 
Figure 7: Tracking task and visual analogue scale. The tracking task was presented in the interval be-
tween two CO2 stimuli. The green square was constantly moving in random directions on the screen and 
the subjects were instructed to keep the red square within the green square by joystick movements. 
Three to four seconds after a CO2 stimulus, the video screen displayed a green visual analogue scale with 
a white bar. By moving the white bar the subjects indicated the magnitude of their pain experience 
during the last presented stimulus. After the rating, the video screen continued to display the tracking 
task.  
 
 
2.5.3.2.3 Quantification of pain and analgesia by means of functional magnet-
ic resonance imaging (fMRI)  
In addition to the psychophysical methods, functional magnetic resonance imaging (fMRI) was 
used to study the cerebral pain network during painful stimulation (Figure 8). By means of 
fMRI it is possible to record event related activation of brain regions, e.g. brain activation due 
to the nociceptive stimulation by CO2. The ability of fMRI to measure brain activity is based on 
the increase of the blood flow to local vasculature after an increase of oxygen consumption 
that accompanies neural activity in the brain. This increase of blood flow occurs with a delay of 
approximately one to five seconds after neuronal activation and rises to a peak over four to 
five seconds before falling back to baseline levels. This results in a corresponding local reduc-
tion of deoxyhemoglobin as the increase in blood flow occurs without an increase of similar 
magnitude in oxygen extraction. Since deoxyhemoglobin is paramagnetic, it alters the T2* 
weighted magnetic resonance imaging signal [71, 72]. Thus, deoxyhemoglobin is referred to as 
an endogenous contrast enhancing agent. The mechanism is an indirect measure for neuronal 
activity and is called the blood-oxygenation level dependent effect (BOLD-effect). The magnet-
ic field is generated by a MRI scanner. The MRI scanners have a typical magnetic field strength 
Tracking task Visual analogue scale
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of 0.3 to 3.0 tesla (T), which is approximately 6,000 to 60,000 times greater than the earth 
magnetic field.  
Figure 8: Funtional magnetic resonance imaging. Upper left picture presents the average increase of 
blood flow or MRT signal with time (blue line, grey dots present the single events), respectively, of a 
brain  region  with  event  related  neuronal  activity  after  a  specific  stimulus  (red).  The  other  pictures 
present a sagittal (upper right), horizontal (lower left) and frontal (lower right) slice of subjects with 
painful CO2 stimulus related increase of neuronal activity in the insular cortex and cingular cortex, re-
spectively, indicated by the yellow areas in the slices.   
 
 
Brain activation of subjects was recorded while they received painful CO2 stimuli. Functional 
activity of the brain determined from the magnetic resonance signal has been repeatedly used 
to determine brain areas involved in the processing of pain [9]. In addition, it has been shown 
to reliably assess the effects of morphine [73] and remifentanil [74] on pain related brain acti-
vation. After opioid treatment, a decrease of the pain related activation in the pain processing 
areas is expected. A 3.0 T magnetic resonance head scanner (Siemens Magnetom Allegra, Sie-
mens AG, Erlangen, Germany) equipped with a 4-channel head coil was used to investigate 
pain related brain activation. The blood-oxygenation level dependent (BOLD) response to pain-
ful CO2 stimuli was recorded by employing an event-related design, which means that acquisi-
tion and stimulus application were synchronized (Figure 9). Imaging parameters of the em-
ployed gradient echo EPI sequence were: parallel imaging method: GRAPPA (reduction factor R 
= 2), TE/TR 30 ms/1530 ms, FA 90°, 29 slices, distance factor 40%, matrix size 64x64, voxel size 
3x3x3 mm. Additionally, a magnetic field mapping was performed with the identical slice posi-
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tions and geometric parameters, and then used for an offline correction of distortions of the 
echo-planar images resulting from inhomogeneities of the B0 field [75, 76]. 
Figure 9: Paradigm of CO2 stimulus-correlated functional magnetic resonance imaging (fMRI). Before 
alfentanil administration and at each alfentanil concentration level, 24 specific nociceptive stimuli, con-
sisting of short (300 msec) pulses of gaseous carbon dioxide (CO2; 66% v/v) were delivered to the nasal 
mucosa of the right nostril. To avoid adaptation and habituation to the pain stimuli, an interstimulus 
interval of 26 sec was used [58]. In each session 392 volumes were acquired which took about 10 min. 
 
 
2.5.4  Assessment of respiratory depression 
2.5.4.1  Provoking hyperventilation by means of CO2 re-breathing  
Respiratory depression was assessed by means of CO2 re-breathing. The CO2 re-breathing was 
executed according to Read´s method [77] with slight modifications. The subjects were in-
structed to re-breathe into a plastic bag connected to a special device (Oxycon Pro, Jaeger, 
Hoechberg, Germany) that continuously records the minute expiratory volume (VEmin), end-
tidal CO2 levels (pCO2) and ventilatory rate. The re-breathing leads to an increase of the CO2 
concentration in the plastic bag and as a consequence in the lungs and the body fluids. The 
progressive rise of the CO2 concentration in the body fluids due to the continuing metabolism 
results in an activation of chemoreceptors in the respiratory center. Thus, breathing is further 
stimulated, finally resulting in hyperventilation, which is indicated by an increase of the minute 
expiratory volume (VEmin). To prevent the development of any hypoxic stimulus to the ventila-
tion [77], the plastic bag was enriched with oxygen (O2). The high initial O2 concentration in the 
re-breathing bag provides enough O2 for metabolism. The slope of the linear relationship be-
tween the VE[min] and pCO2 (
x
y
 
 
; Figure 10) is defined as the primary target parameter for the 
quantification of the respiratory depressive effect. In addition, another reliable parameter is 
392 fMRI recordings
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the expiratory volume per minute at a CO2 concentration of 55 mmHg (VE(55mmHg pCO2)), which 
can be calculated from the slope and intercept of the obtained linear relationship between 
expiratory volume and CO2 concentration [78]. While changes in the x- and y- intercepts can be 
misleading  and  therefore  should  not  be  used  as  parameter,  a  decrease  in  the  slope  and 
VE(55mmHg pCO2) can be considered as a reliable indication for respiratory depression during opioid 
treatment. This method has repeatedly demonstrated to reliably asses the respiratory depres-
sive effects of morphine [60, 79]. 
Figure 10: Assessment of the respiratory depression by means of CO2 re-breathing. Fictitious data 
acquired during a typical CO2-rebreathing test. The minute expiratory volume VE rises with increasing 
CO2 concentration (dots). Data is analyzed by fitting a linear equation to the data. Respiratory depres-
sion is indicated by a decrease of the slope of the linear relationship or a decrease of the minute expira-
tory volume at a CO2 concentration of 55 mmHg (VE(55mmHg pCO2)). 
 
 
2.5.4.2  Monitoring of spontaneous respiration 
Additionally, opioid induced respiratory depression was measured by analyzing changes of the 
frequency of spontaneous breathing. Therefore, a respiratory belt transducer (MLT1132 Piezo 
Respiratory Belt transducer, ADInstruments GmbH, Spechbach, Germany; Figure 11) was fas-
tened around the subject’s upper abdomen and connected to an integrated data recording 
unit featuring a built-in amplifier (Powerlab 4/25T, ADInstruments GmbH, Spechbach, Germa-
ny). The subjects were instructed to remain silent, while recording their respiratory frequency 
for a period of 10 min, during which slow music was played and the laboratory was otherwise 
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kept completely silent. The first three and the last minute were rejected from analysis. Respi-
ratory depression is indicated by a decrease in the respiratory frequency (Breaths/minute). 
Figure 11: Monitoring of spontaneous respiration. Fictitious data acquired during the experiment. Each 
peak represents a single breath. Results were presented as number of breaths per minutes.  
 
 
2.5.5  Assessment of opioid related medical symptoms 
Medical symptoms reported by the subjects and the occurrence of vomiting were recorded by 
the investigator. Opioid related side-effects such as tiredness, sickness, drowsiness, euphoria, 
vertigo, and itching were rated by the subject using visual analogue-scales (VAS, length 100mm 
ranging from 0=”no such symptom” to 100=”symptom experienced at maximum”). 
2.6  Assessment of µ-opioid receptor expression and function in 
post mortem human brain tissue 
2.6.1  OPRM1 mRNA expression analysis 
OPRM1 mRNA expression was assessed by means of real-time PCR (rt-PCR). Therefore, mes-
senger-RNA (mRNA) was isolated from tissue by means of the EZ1 RNA Universal Tissue Kit 
(Qiagen, Hilden, Germany). After reverse transcription of RNA (30 ng/μl) using random hex-
amers and the High capacity cDNA Archive Kit (Applied Biosystems, Darmstadt, Germany), rt-
PCR was performed with 50 ng RNA-equivalent in triplicates using the Taqman Universal PCR 
Master Mix without Amperase
® UNG and the validated TaqMan
® gene expression assay for the 
OPRM1 gene (Hs00168570_m1, Applied Biosystems, Germany). This generated an amplicon of 
67  base  pairs  (bp)  corresponding  to  the  NM_000914.2  transcript 
(http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000914.2).  The  ACTB  (β-Actin) 
RNA was employed as endogenous housekeeping gene (Hs99999903_m1, Applied Biosystems, 
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Germany)  generating  a  171  bp  long  amplicon  from  the  NM_001101.2  transcript 
(http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_001101.2).  Quantification  of 
mRNA was conducted on a Taqman 7900HT platform (Applied Biosystems, Darmstadt, Germa-
ny) by IMGM Laboratories GmbH (Gene Expression Center Martinsried, Martinsried, Germa-
ny). From raw fluorescence data, a threshold cycle value, Ct, corresponding to the cycle num-
ber at which the fluorescence signals of the reporter dye passed a fixed threshold (ten stan-
dard deviations from the baseline) on the amplification plot was obtained for each sample 
(Sequence Detection Software, SDS version 2.0; Applied Biosystems). This ensured that the Ct 
value was proportional to the number of RNA copies present at the start of the PCR. Negative 
controls showed no amplification in the range of Ct < 40 indicating the absence of cross-
contamination and unspecific amplification of primer or sensor dimers. OPRM1 mRNA expres-
sion was determined using the comparative Ct method as described by  
( )
( ) ( )
control x
relative
Ct reference sample Ct reference sample
Ct
xpression
Ct Ct Ct Ct Ct
mR A OPRM
− − − =   
= −
   − 2          2 1   e
       Equation 1, 
where Ctsample and Ctreference stand for the Ct values for the OPRM1 and ACTB mRNA samples, 
respectively, being the respective means of three analysis repetitions from control and the 
sample of interest. To test whether OPRM1 mRNA expression differed between genotypes and 
brain regions, a sample with the Ct value closest to the median of the Ct values of the second-
ary somatosensory cortex SII of the wildtype group was chosen to serve as Ctcontrol.  
2.6.2  Tissue preparation for binding assays 
Tissue samples (1-1.5 g) were homogenized with a fast rotating Ultra-Turrax (Janke & Kunkel 
GmbH, Staufen i. Breisgau, Germany) in 10-15 volumes of homogenization buffer (10 mM Tris-
HCl pH 7.4, 290 mM D(+)-Saccharose). The crude tissue lysate was immediately centrifuged at 
1,000×g at 4°C for 15 min and the supernatant recentrifuged at 45,000×g, 4°C for 45 min. The 
pelleted proteins were resuspended in ice-cold isolation medium (50 mM Tris-HCl pH 7.4) and 
used for experiments or stored at -80°C.  
2.6.3  Protein concentration analysis 
Protein concentrations were measured by the method of Bradford [80]. 10 µl of the mem-
brane suspensions were diluted in water to a final volume of 100 µl. 10 µl of the resulting dilu-
tion were transferred into a 96 well plate. Subsequently, 190 µl of Bradford reagent were add-儠Ч
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ed to each well. Within 5 to 15 minutes the absorption at 595 nm was measured. The amount 
of protein in each sample was calculated by means of a concomitantly measured calibration 
curve of in water diluted bovine serum albumine (BSA) in the concentration range of 0 to 7 
ng/ml. The protein concentrations of the membrane suspensions of the brain samples were 
usually between 1.4 and 7.8 ng/ml. 
2.6.4  [3H]-DAMGO binding assays 
2.6.4.1  Saturation binding 
The µ-opioid receptor affinity (KD) and µ-opioid receptor density (BMax) of the secondary soma-
tosensory SII and lateral thalamus were assessed by measuring the saturation binding of the μ-
opioid receptor specific radioligand [
3H]-DAMGO (Perkin Elmer Life Sciences Inc., Boston, MA, 
USA). To determine the total binding of [
3H]-DAMGO to the membrane proteins, equal vo-
lumes of membrane proteins (25 μl) were diluted in a final volume of 250 μl assay buffer (50 
mM Tris-HCl pH 7.4) and incubated with at least 10 different concentrations of [
3H]-DAMGO in 
the range of 0.07 nM – 14.42 nM. In addition, to determine the non-specific binding of [
3H]-
DAMGO to the membrane proteins, equal volumes of membrane proteins were incubated 
with 0.07 nM and 14.42 nM [
3H]-DAMGO, respectively, in the presence of 10 μM naloxone 
(Naloxon-Curamed,  Curamed,  Karlsruhe,  Germany). KD([
3H]-DAMGO)  and  BMax([
3H]-DAMGO) 
were calculated by non-linear regression of the specific binding according to the equation: 
)) ] ([ ) ] ([ (
) ] ([ ) ] ([
) ] ([ 3 3
3 3
3
DAMGO H F DAMGO H K
DAMGO H F DAMGO H B
DAMGO H B
D
Max
− + −
− × −
= −       Equation 2, 
where B([
3H]-DAMGO) is the concentration of μ-opioid receptor bound [
3H]-DAMGO (specific 
binding), F([
3H]-DAMGO) the concentration of the free [
3H]-DAMGO, BMax([
3H]-DAMGO) the 
maximum  number  of  [
3H]-DAMGO  binding  sites  (μ-opioid  receptor  density)  and  KD([
3H]-
DAMGO) the equilibrium dissociation constant of [
3H]-DAMGO. Specific [
3H]-DAMGO binding 
to the membranes was calculated by subtraction of non-specific binding from total binding. 
2.6.4.2  Displacement binding 
In addition, the ability of the μ-opioid receptor agonists morphine, morphine-6-glucuronide 
(M6G), alfentanil, methadone and human β-endorphin to displace [
3H]-DAMGO from the μ-
opioid receptor in the secondary somatosensory area SII was measured. Therefore, membrane 
proteins were incubated with increasing concentrations (0 nM–10 μM) of the unlabelled agon-ٖ 瞰
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ists in the presence of 2.5 nM [
3H]-DAMGO to determine the agonist concentration needed to 
displace half of the μ-opioid receptor bound [
3H]-DAMGO, IC50(Agonist).  
Displacement binding data was normalized, whereas the zero percent value was obtained from 
incubation of 2.5 nM [
3H]-DAMGO in the presence of 10 μM unlabeled agonist and 100 per-
cent value was obtained from incubation with 2.5 nM [
3H]-DAMGO in the absence of unlabeled 
agonist. The IC50(Agonist) was determined using non-linear-regression according to the equa-
tion: 
) ( log ) ( (log
3
50 10 1
100
) ] ([ Agonist L Agonist IC DAMGO H B − +
= −            Equation 3, 
where L(Agonist) is the competitor concentration, and B([
3H]-DAMGO) is the associated bind-
ing rate of [
3H]-DAMGO. Considering that the concentration and KD of the radioligand affects 
the true position of the displacement binding curve, it is necessary to correct the IC50(Agonist) 
values to obtain the radioligand independent inhibition constant KI (Agonist) for the competi-
tor. Thus, the obtained IC50(Agonist) are corrected by the method of Cheng and Prusoff [81] 
according to the equation:  
1
) ] ([
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I
             Equation 4, 
whereas LV([
3H]-DAMGO) is the concentration of [
3H]-DAMGO (2.5 nM) and KD([
3H]-DAMGO) is 
the [
3H]-DAMGO related equilibrium dissociation constant measured in the saturation binding 
experiment. 
The experiments were carried out at a constant temperature of 25°C while shaking at 1,000 
rpm (Thermomixer compact, Eppendorf, Hamburg, Germany). After an incubation period of 
120 minutes, the membrane bound [
3H]-DAMGO was separated from unbound [
3H]-DAMGO 
by rapid filtration through Whatman GF/B filters (Whatman plc, Brentford, Middlesex, UK), 
followed by six washes with 1 ml of ice-cold assay buffer. The filters were transferred into vials 
(Zinsser Polyvials
®, Zinsser Analytic GmbH, Frankfurt, Germany), filled with 5 ml of scintillation 
liquid (Quicksafe
® A, Zinsser Analytic GmbH, Frankfurt, Germany) and the decays per minute 
(dpm) of the filter bound [
3H]-DAMGO were counted by a Liquid Scintillation Analyzer (Packard 
Tri-Carb
® 2100TR, Canberra-Packard Central Europe GmbH, Schwadorf, Austria). ٖ 瞰
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2.6.5  [35S]-GTPγS binding assays 
The ability of DAMGO (Sigma-Aldrich, St. Louis, MO, USA) to activate intracellular μ-opioid 
receptor signaling was measured by means of the [
35S]-GTPγS binding assay. Therefore, mem-
brane proteins (40 μg) of the secondary somatosensory cortex SII and thalamus were diluted in 
a final volume of 250 μl assay buffer. The assay buffer contained 50 mM Tris pH 7.4, 100 mM 
NaCl, 0.2 mM EGTA, 3 mM MgCl2, 1 mM DTT, 50 µM GDP, 0.5 nM [
35S]-GTPγS (Amersham Bios-
ciences, Uppsala, Sweden) and increasing concentrations (0 nM–100 µM) of DAMGO. Follow-
ing an incubation period of 120 min at a temperature of 25°C while shaking at 1,000 rpm, the 
reaction was terminated by rapid filtration through Whatman GF/B filters, followed by six 
washes with 1 ml of ice-cold washing buffer (50 mM Tris pH 7.4, 100 mM NaCl, 0.2 mM EGTA, 
3 mM MgCl2). Subsequently, filters were placed in scintillation vials containing 5 ml liquid scin-
tillation cocktail and decays per minute (dpm) of the filter bound [
35S]-GTPγS were measured. 
The basal binding of [
35S]-GTPγS without stimulation of DAMGO, B0(DAMGO), the maximum 
binding of [
35S]-GTPγS after stimulation of DAMGO, BMax(DAMGO), and the concentration of 
DAMGO needed to stimulate half maximal [
35S]-GTPγS binding, EC50(DAMGO), were deter-
mined according to the equation:  
)) ( log ) ( (log
35
0
35
35
0
35
50 10 1
) ] ([ ) ] ([
) ] ([ ) ] ([ DAMGO L DAMGO EC
Max S GTP S B S GTP S B
S GTP S B S GTP S B − +
− − −
+ − = −
γ γ
γ γ     Equation 5, 
where L(DAMGO) denotes the DAMGO concentration and B([
35S]-GTPγS) the associated bind-
ing rate of [
35S]-GTPγS. Subsequently, DAMGO related net [
35S]-GTPγS binding per µ-opioid 
receptor, BNet(DAMGO), was calculated according to the equation:  
) ( ) ( ) ( 0 DAMGO B DAMGO B DAMGO B Max  et − =            Equation 6. 
For each brain region, the net effect of agonist binding per µ-opioid receptor was calculated as 
the quotient of the net DAMGO stimulated [
35S]-GTPγS binding data and the µ-opioid receptor 
density,  
) ] ([
) (
3 DAMGO H B
DAMGO B
Max
 et
−                  Equation 7. 
This analysed whether the G-protein activation correlated with the respective µ-opioid recep-
tor densitiy in the analysed brain region and allowed for comparison of the efficacy of µ-opioid 
receptor coupling to G-proteins between brain regions and genotype groups [82-84]. ٖ 瞰
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2.7  Data analysis 
2.7.1  Investigation of pain-related brain activation during alfentanil admin-
istration in non-carriers and homozygous carriers of OPRM1 118A>G 
SNP 
Spatial pre-processing and statistical analyses were performed using the statistical parametric 
mapping software SPM2 (Wellcome Department of Imaging Neuroscience, London, UK) [85, 
86]. Data were corrected for acquisition time (slice timing), realigned to the first volume for 
motion  correction  [87],  spatially  normalized  [88]  to  a  standard  EPI  template  [89],  and 
smoothed using a 9 mm full width at half maximum isotropic Gaussian kernel. Data analysis 
employed  voxel-wise  estimation  of  regression  coefficients  according  to  the  general  linear 
model as implemented in SPM2 [87], where painful stimuli were modeled by the built in ca-
nonical hemodynamic response function. Low frequency fluctuations were removed with a 
high pass filter with a cutoff at 128 s. The single subject analyses resulted in a contrast image 
for each subject and each alfentanil brain concentration level. Subsequently, these contrast 
images were incorporated into a second level analysis of variance to assess the influence of the 
alfentanil brain concentrations on the brain responses to painful stimuli. In a first step, statisti-
cally significant pain-related brain activation at each alfentanil concentration level was tested 
with appropriate contrasts in non-carriers of SNP ORPM1 118A>G, setting the level of interest 
as 1 and the remaining levels to 0, e.g. main effects of level 0 tested by contrast (1 0 0 0 0), 
main effects of level 1 tested by contrast (0 1 0 0 0) and so forth. Subsequently, for analysis of 
the relation between alfentanil brain concentration and pain-related brain activation in wild-
type subjects, the following contrasts were used: (1) A linear function (1.5 0.5 -0.5 -1.5 0), de-
tecting brain regions with linear concentration-dependent alfentanil effects and (2) a step 
function (3 -1 -1 -1 0), detecting brain regions with non-concentration-dependent alfentanil 
effects. To illustrate brain regions displaying predominantly concentration-dependent or con-
centration-independent alfentanil effects, each contrast was exclusively masked by the other 
one at p < 0.001, uncorrected. In addition, contrast (1) was inclusively masked with contrast (2) 
allowing for detection of brain regions where the pain-related activation showed intermediate 
behavior. The resulting statistical parametrical maps of t- statistics were interpreted with re-
gard to the probabilistic behavior of Gaussian random fields [90]. Results are only reported if 
they were at least significant at an FDR (False Discovery Rate) corrected level of p<0.05. In the 
second step, areas with significant alfentanil effects on pain related activation in non-carriers ٖ 瞰
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of SNP ORPM1 118A>G were defined as regions of interest for the analysis of the pharmaco-
genetic effects of SNP ORPM1 118A>G. Thus, activations in the regions of interest were cor-
rected for multiple comparisons within a sphere of 15 mm radius (small volume correction). 
The influence of the SNP ORPM1 118A>G on the identified concentration-dependent alfentanil 
effects was analyzed using contrasts: 1.5 0.5 -0.5 -1.5 0 -1.5 -0.5 0.5 1.5 0, indicating levels 0 – 
4 for non-carriers and levels 0 – 4 for carriers of SNP ORPM1 118A>G. Similarly, concentration 
independent effects were analyzed using the 3 -1 -1 -1 0 -3 1 1 1 0, again indicating levels 0 – 4 
for non-carriers and levels 0 – 4 for carriers of SNP ORPM1 118A>G. Level 4 was excluded from 
alfentanil concentration effects analysis because it was only included in the experiment as 
additional measurement to demonstrate the reversibility of opioid effects. Therefore, level 4 is 
set to 0 in the alfentanil concentration effects analysis. Results were only reported if they were 
at least significant at an FDR (False Discovery Rate) corrected level of p<0.05. Localizations of 
significant results are reported as MNI (Montreal Neurological Institute) coordinates (mm).  
2.7.2  Investigation of µ-opioid receptor expression and function in pain 
processing brain regions of non-carriers and carriers of OPRM1 
118A>G SNP 
Equations parameters (Eq 1 – 7) were fitted to the respective data separately for each subject 
(GraphPad Prism
® 5, GraphPad Software, San Diego, CA, USA). Effects of OPRM1 118A>G SNP 
on  2
-ΔΔCt,  BMax([
3H]-DAMGO),  KD([
3H]-DAMGO),  B0(DAMGO),  BMax(DAMGO),  BNet(DAMGO), 
EC50(DAMGO) and on the quotient of DAMGO stimulated net [
35S]-GTPγS binding to µ-opioid 
receptor density (BNet(DAMGO)/BMax([
3H]-DAMGO)) were analysed by means of multivariate 
analysis of variance for repeated measures (rm-ANOVA), with “region” (i.e., SII or thalamus; 
degrees of freedom, df=1) as within-subject factor and “118A>G” (i.e., 118AA, 118AG, 118GG; 
df=2) as between-subject factor (SPSS 12.0.2, SPSS Inc., Chicago, IL, USA). The effects of the 
OPRM1 118A>G SNP on KI (Agonist), were analysed by means of univariate analysis of variance 
with between-subject factors “agonist” (i.e., morphine, M6G, endorphin, methadone and al-
fentanil; df=4) and “118A>G” (i.e., 118AA, 118AG, 118GG; df=2). The α-level was set at 0.05. 
Post-hoc comparisons for statistical main effects were done by t-tests, with α-correction (Bon-
ferroni) when indicated. ٖ 瞰Ļ
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2.7.3  Investigation of the therapeutic range of alfentanil in non-carriers and 
carriers of OPRM1 118A>G SNP 
To judge the consequences of the variant OPRM1 118G allele for the therapeutic range of al-
fentanil, the data were transformed into percent changes from baseline in order to compare 
the different measurements of analgesia and respiratory depression. As a precondition, the 
baselines  were  not  permitted  to  differ  between  genotypes,  which  was  true  in  our  case 
(Kruskal-Wallis tests: p>0.1 for the baseline values of all pharmacodynamic measures). The 
subsequent analysis focused on the comparison of the relationship of these effects to the al-
fentanil plasma concentrations between different pharmacodynamic end points and of the 
consequences of the variant 118G allele for these relationships. 
Simulations of the alfentanil concentrations at effect site based on published pharmacokinetic-
pharmacodynamic parameters of alfentanil with a transfer-half-life between plasma and effect 
site of 1.1 min [61] had shown, that equilibration between effect site and plasma concentra-
tions had been safely reached after 15 min. This was the latency after each change of alfentanil 
target concentrations before pharmacodynamic measurements started. In fact, simulations 
with STANPUMP had shown that less than two minutes were enough to reach the target con-
centration at effect site. Therefore, the effect versus concentration relationship could be con-
fidently calculated using the alfentanil plasma concentrations. For analysis, effects of experi-
ments between the two successive blood samples closest to the actual measurements were 
related to the average concentration calculated from these samples. For example, the average 
concentration of blood sample 1 (15
th min) and 2 (40
th min) was allocated to effects of transcu-
taneous electrical stimulation and CO2 re-breathing in Level 2, which took place between the 
two blood samplings. 
The relationship between the effects of alfentanil and its concentrations was described by a 
power model of  
[ ]
γ
alfentanil % C a Effect ⋅ =               Equation 8, 
whereas a denotes the slope and γ the shape factor of the concentration response relation-
ship. A power model was preferred to a sigmoidal effect versus concentration relationship (i.e., 
an Emax model) because the complete theoretical sigmoidal shape was not observed during the 
study. In contrast, the pharmacodynamic measures did not come close to the maximum theo-
retical effect due to ethical considerations. That is, tolerance to electrical pain could have in-ٖ 瞰
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creased far above the cut-off of 20 mA with very high alfentanil doses. Similarly, respiratory 
depression was only moderate because the healthy volunteers could not have been brought 
into danger. The theoretical maximum being apnoea, i.e., respiratory frequency of zero, was 
not possible to be achieved. Exceptions from this rule are the estimates of the pain intensity of 
the CO2 stimuli, which could have reached zero. However, a sigmoid model provided no better 
fit than the power model, judged by goodness-of-fit assessment as explained later in this sec-
tion and was therefore not used. 
The pharmacokinetic-pharmacodynamic modeling was performed with NONMEM V (version 
1.1, Globomax, Hanover, MD, USA). All concentration and effect data (separately for each par-
ticular pharmacodynamic effect) from all individuals were analyzed in one single step, howev-
er, without pooling the data but maintaining individual assignment for each data point to allow 
for assessment of the parameter values and their interindividual variability in one single step 
as being the standard procedure of population pharmacokinetic-pharmacodynamic modeling 
[91]. The modeling process repeatedly employed goodness-of-fit procedures, which were (i) 
the NONMEM objective function being minus two times the log likelihood (-2LL) and the χ
2 
approximation with the number of degrees of freedom equal to the difference in the number 
of terms between two models (α-level 0.05), (ii) the median absolute weighted residuals, cal-
culated as (measured – predicted) / predicted, and the mean of the individual mean absolute 
weighted residuals, and (iii) visual inspection of the fits versus observed data. Log-normally 
distributed interindividual variance of the slope parameter a was used: 
i e P TV i i
η θ ⋅ = , , where 
Pi is the value of the parameter of the individual, θi,TV is the typical value (TV) of this parameter 
in the population, and η is a variable accounting for the interindividual variability, with mean 
zero and variance ω
2. Normally-distributed interindividual variance of the shape parameter γ 
was used:  η θ + = TV i i P , . Interindividual variability was assigned to parameters of the final 
model in case that this improved the fit. The residual error ε was modeled using an additive 
error model. Proportional or combined proportional  and additive error models resulted in 
worse fits or impossibility to obtain a fit and were therefore rejected. Calculations were per-
formed using “first order conditional estimation” and “η-ε interaction”. Ninety-five percent 
confidence intervals of parameter values were calculated from 200 runs of each of the four 
models for each effect measure (see below) with data sets that were obtained by Bootstrap 
resampling from the original data set [92], using Wings for NONMEM (N. Holford, Auckland, NZ ٖ 瞰
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[93]; http://wfn.sourceforge.net/index.html). The 95% confidence intervals of the parameter 
values were obtained as the 2.5
th and 97.5
th percentiles of the results of the 200 model runs.  
The influence of the OPRM1 118G SNP on the model parameters was assessed as follows: First, 
it was checked whether a particular parameter varied interindividually. If this was found to be 
the case, which was true for the slope parameter a (Equation 1), it was assessed whether the 
variability was partly explained by the presence of the 118G allele. This was done by multiply-
ing the model parameter found to exhibit interindividual variability with 1 in case of wild-type, 
with a factor θ1 in case of the presence of the 118G allele (i.e., genotype 118AG and 118GG). 
The alternatives were multiplying the model parameter with 1 in case of wild-type and hetero-
zygous carriers of the 118G allele (i.e., genotype 118GG), or multiplying the model parameter 
with 1 in case of wild-type, with a factor θ1 in case of heterozygous presence of the mutation, 
and with a factor θ2 in case of homozygous presence of the mutation. The final model was 
identified on the basis of goodness-of-fit assessment as described above. Thus, identification 
of a pharmacogenetic influence of the OPRM1 118A>G SNP was based on the likelihood ratio 
test. This test compares the NONMEM objective functions being minus two-times the log like-
lihood (-2LL) between two models, i.e. the reduced and the full model. The reduced model in 
the present context contains only one parameter a for the slope of the linear effect vs. concen-
tration relationship for all genotypes (Equation 1). The full model contains in addition the fac-
tors θ1 and θ2. The likelihood ratio test focuses on the difference between the values of -2LL 
using the χ
2 approximation with the number of degrees of freedom equal to the difference in 
the number of terms between two models. We tested whether introduction of one or two 
additional parameters (θ1 and θ2.) into the model provided a statistically significant improve-
ment of the fit of the data. For one parameter, statistical significance was reached at an α-
level of 0.05 when the introduction of one parameter into the model resulted in a decrease in -
2LL by ≥3.84, and at an α-level of p=0.01 when -2LL decreased by ≥6.63. For two parameters 
the respective reductions in -2LL were ≥5.99 and ≥9.21 for α-levels of 0.05 and 0.01, respec-
tively. This is a standard procedure in population modeling with NONMEM [91]. In addition to 
the OPRM1 118A>G SNP, influences of the subjects’ sex were analyzed analogously. 
Based on the identified models, the alfentanil concentrations required for 50% analgesia or 
50% change in parameters of respiratory depression were calculated for the identified groups 
with respect to the 118A>G polymorphism.  ٖ 瞰Ļ
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Comparisons of the body mass index, alfentanil doses, frequency of vomits or magnitude of 
other medical symptoms, and of the gender distribution among OPRM1 genotypes were per-
formed using Kruskal-Wallis tests, Wilcoxon signed rank tests or the Fisher’s exact test, where 
appropriate. These additional statistics were performed using the SPSS statistical software 
(version 12.0.2, SPSS Inc., Chicago, IL, USA).  
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3  Results 
3.1  Pain-related brain activation in non-carriers and homozyg-
ous carriers of OPRM1 118A>G SNP during alfentanil admin-
istration 
3.1.1  Pain-related brain activation in non-carriers of SNP ORPM1 118A>G 
Pain-related activation was detected in non-carriers of the SNP ORPM1 118A>G bilaterally in 
the insular cortex (x, y, z (mm), -30, 18, 9 and 36, 24, 6 at the left and right hemisphere, re-
spectively), the primary somatosensory area SI (x, y, z, -63, -18, 21 and 63, -18, 24, respective-
ly), the secondary somatosensory area SII (x, y, z, -57, 0, 12 and 60, -15, 21, respectively), the 
parahippocampal gyrus, amygdala and superior temporal gyrus (temporal pole) (x, y, z, -21, 3, -
15 and, 36, 6, -15, respectively), the anterior cingulate cortex (x, y, z, -6, 6, 42 and 6, 15, 39, 
respectively), and the supplementary motor area (x, y, z, -6, 6, 45 and 6, 3, 63, respectively).  
3.1.2  Effects of increasing alfentanil concentrations on pain-related brain 
activation in non-carriers of SNP ORPM1 118A>G 
Stepwise increasing alfentanil concentrations led to a decrease in both, magnitude and extent 
(t-values and cluster size, respectively; Figure 12 and Table 2), of pain-associated brain activa-
tion, up to an absence of activation at the highest alfentanil concentration level. This decrease 
in pain related brain activation was accompanied by a decrease in subjective pain perception 
(Figure 12; analysis of variance for repeated measures: p<0.001 for the within-subjects effect 
of “alfentanil concentration level”; α-corrected post-hoc t-tests indicating significant differenc-
es of concentration level 3 from concentration level 0 at p<0.01). With decreasing alfentanil 
concentrations at level 4, pain-associated activation reappeared in all brain regions, indicating 
that the decrease of activation during level 1 to 3 was opioid related. 
   ٖ 瞰
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Figure 12: Pain-associated brain activation at different concentrations of alfentanil in non-carriers of 
SNP OPRM1 118A>G. The glass brains show decreasing pain-associated brain activation (p<0.05 FWE 
corrected) with increasing alfentanil concentrations. The  mean alfentanil plasma concentrations are 
given as thick solid lines below the glass brains, and the individual concentrations are indicated as dots 
connected with thin dotted lines. Decreasing pain-related brain activation with increasing alfentanil 
concentrations was associated with a reduction of the individual pain ratings, given at the bottom as 
bars. At the additional level 4 at 20 min after the alfentanil infusion was stopped, we observed partial 
restitution of pain related brain activation, associated with restitution of the painfulness of the stimuli. 
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Table 2: Brain regions with pain-associated activation at different alfentanil concentrations in non-
carriers of SNP OPRM1 118A>G. Pain-related brain activation observed at baseline (Level 0; 0 ng/ml 
Alfentanil) decreased with increasing alfentanil concentrations (Level 1 and 2; 47.2 and 76.6 ng/ml, re-
spectively) until it vanished completely at the highest concentration of alfentanil (Level 3; 76.6 ng/ml). It 
reappeared after the end of infusion with decreasing alfentanil concentrations (Level 4; 47.8 ng/ml). 
Presented results are statistically significant at p<0.05, FDR corrected at voxel level (MNI: Montreal 
Neurological Institute; * p<0.05 FWE corrected at voxel level). 
    MNI coordinates  Main effects, voxel-level (T) 
Anatomic location     x  y  z  Level 0  Level 1  Level 2  Level 3  Level 4 
Insula 
L 
-30  18  9  8.06*  3.89  —  —  3.52 
-36  12  -3  6.54*  4.55  —  —  — 
-36  -9  3  7.45*  5.36*  3.98  —  5.57* 
-33  -15  15  5.06*  4.78  3.62  —  5.08* 
-33  -15  18  4.54  5.13*  3.94  —  5.25* 
R 
36  24  6  7.81*  4.55  —  —  4.07 
33  21  9  7.34*  5.20*  —  —  4.11 
39  15  -3  7.30*  3.52  —  —  — 
36  -9  9  4.69  5.72*  3.43  —  5.60* 
36  -9  21  4.56  4.22  5.12  —  3.86 
SI  
(Postcentral Gyrus,  
Supramarginal Gyrus) 
L 
-63  -18  21  5.84*  5.05*  4.66*  —  4.09 
-60  -21  18  5.42*  5.39*  5.62*  —  4.76 
-63  -24  18  4.84  5.37*  5.09*  —  5.21* 
R 
54  -12  27  3.92  —  —  —  — 
63  -18  24  6.77*  4.78  3.27  —  3.91 
60  -15  27  5.64*  4.08  —  —  3.32 
SII  
(Rolandic Operculum) 
L 
-57  0  12  7.10*  5.34*  4.33  —  5.82* 
-57  0  6  6.22*  —  3.62  —  5.83* 
-57  -3  9  6.91*  5.41*  3.9  —  6.36* 
R 
60  -15  21  6.63*    3.26  —  4.21 
60  -12  15  6.11*  5.86*  5.02*  —  5.14* 
57  -12  15  6.07*  5.73*  4.94*  —  4.86 
Parahippocampal Gyrus,  
Amygdala,  
Superior Temporal Gyrus 
L 
-24  3  -24  4.25  —  —  —  — 
-18  3  -21  3.56  —  —  —  — 
-21  3  -15  5.01*  —  —  —  — 
-36  0  -18  4.69  —  3.49  —  4.56 
-42  -6  -21  3.81  3.50  —  —  4.65 
R 
24  6  -24  5.25*  —  —  —  3.73 
36  6  -15  6.05*  4.23  —  —  3.54 
60  6  -3  4.07  3.62  4.30  —  3.54 
Anterior Cingulate 
L  
-6  6  42  5.26*  —  —  —  — 
-9  9  42  5.08*  —  —  —  3.48 
R 
6  15  39  4.97*  3.86  —  —  — 
6  12  39  4.83  3.81  —  —  3.38 
6  21  42  3.28  —  —  —  — 
Supplementary Motor Area /  
Median Cingulate 
L   -6  6  45  5.25*  —  —  —  — 
R/L  0  0  63  4.31  —  —  —  — 
R  6  3  63  3.57  —  —  —  — 
Posterior Cingulate 
L   -6  -30  24  —  —  —  —  4.66 
R  6  -33  27  3.51  —  —  —  3.93 ռ ￿
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Pain-associated brain activation displayed two distinct main patterns with respect to alfentanil 
effects. Alfentanil produced predominantly linear concentration-dependent effects (statistical 
SPM contrast 1.5 0.5 -0.5 -1.5 for levels 0 – 3, respectively; Figure 13 and Table 3) on pain-
related brain activation at the right primary somatosensory area SI and at the left somatosen-
sory area SII. A similar behavior was observed in the posterior parts of the left and right insula. 
In contrast, concentration-independent alfentanil effects (statistical SPM contrast 3 -1 -1 -1 for 
levels 0 – 3, respectively) on pain-related brain activation were observed in the right parahip-
pocampal gyrus and amygdala, and in the most anterior part of the left insula. An exception 
from this duality of clearly concentration-dependent or independent effects was seen in large 
parts of the left and right median insula, in the anterior cingulate cortex and in the amygdala, 
where an intermediate behavior dominated the alfentanil effects on brain activation. 
 
 
 
 
 
 
 
Figure 13: Brain regions displaying a predominantly linear, intermediate or predominantly step-like 
negative  correlation  of  pain-related  activation  with  increasing  alfentanil  concentrations  in  non-
carriers of SNP OPRM1 118A>G (from top to bottom). The activation decreased predominantly linearly 
in regions related to the processing of sensory information, i.e. the primary somatosensory area SI, the 
secondary somatosensory area SII, and the posterior part of the insular cortex (contrast 1.5 0.5 -0.5 -1.5 
0 exclusively masked by 3 -1 -1 -1 0 at p<0.001 uncorrected; yellow colored areas). Intermediate concen-
tration-dependent behavior was seen in more anterior parts of the insular cortex, which increasingly 
processes affective instead of the sensory dimensions of pain, and in the anterior cingulate cortex, a 
multi-integrative structure of stimulus perception involved in affective and attentional processing of 
pain (3 -1 -1 -1 0 exclusively masked by 1.5 0.5 -0.5 -1.5 0 at p<0.001 uncorrected; red colored areas). In 
contrast, activation in parts of the amygdala, processing affective components of pain, decreased in a 
step-like concentration-independent manner (cyan colored areas; contrast 1.5 0.5 -0.5 -1.5 0 inclusively 
masked by 3 -1 -1 -1 0 at p<0.001 uncorrected). The right column visualizes the contrast estimates at the 
location with the highest T-value within these regions.  ٝ
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3.1.3  Consequences of SNP OPRM1 118A>G for alfentanil effects on pain-
related brain activation 
The consequences of SNP OPRM1 118A>G for the alfentanil effects on pain-associated brain 
activation were predominantly observed at brain regions where the pain-associated activation 
decreased linearly or intermediately with increasing alfentanil concentrations, but not in re-
gions with a step-like concentration-independent response (Figure 14 and Table 4). These re-
gions included the primary somatosensory cortex SI, the insular cortex and the anterior cingu-
late cortex.  
Table 4: Brain regions displaying differences in the negative correlation of pain related activation be-
tween carriers and non-carriers of SNP OPRM1 118A>G. Areas with significant alfentanil effects on pain 
related activation in non-carriers of µ-opioid receptor variant N40D were defined as regions of interest 
for the analysis of the pharmacogenetic effects of µ-opioid receptor variant N40D. Activations in the 
regions of interest were corrected for multiple comparisons within a sphere of 15 mm radius (small 
volume correction). Statistical significant differences between carriers and non-carriers of μ-opioid re-
ceptor variant N40D were observed only in brain regions with a predominantly linear or intermediate 
decrease of pain-related brain activation and not in areas with a predominantly step-like decrease. Pre-
sented results are statistically significant at p<0.05, FDR corrected at voxel level (MNI: Montreal Neuro-
logical Institute; * p<0.05 FWE corrected at voxel level). 
 
   
Predominantly linear 
1.5 0.5 -0.5 -1.5 0 -1.5 -0.5 0.5 1.5 
    MNI coordinates  voxel-
level (T)  Anatomic location    x  y  z 
Insula  R 
36  27  3  3.95* 
39  15  -3  3.85* 
           
SI (Postcentral Gyrus)  R 
54  -36  57  3.38* 
54  -12  27  3.56* 
           
Anterior Cingulate  R  6  18  42  3.38* 
           
Posterior Cingulate  R  6  -36  24  3.71* 
           
Supplementary Motor area  
/Median Cingulate 
R  6  3  63  3.51* 
    ٝ
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Figure 14: Brain regions displaying differences in the negative correlation of pain related activation 
between carriers and non-carriers of SNP OPRM1 118A>G. The influence of SNP OPRM1 118A>G on the 
concentration dependent decrease of pain-related brain activation was only existent in regions of the 
right brain hemisphere with a predominantly linear or at most intermediate decrease of brain activation 
(contrast 1.5 0.5 -0.5 -1.5 0 -1.5 -0.5 0.5 1.5 0 at p<0.001 uncorrected). The right column visualizes the 
contrast estimates at the location with the highest T-value within these regions of non-carriers of SNP 
OPRM1 118A>G (solid white columns) and of carriers of SNP OPRM1 118A>G (solid red columns). Step-
like contrasts did not display any significant genotype difference (Table 4) and are therefore omitted. 
 
 
   
Anterior Cingular Cortex 0
1
2
3
4
T value
 
Insular Cortex contrast estimate
at [36, 27, 3]
L0
L1
L2
L3
L4
L0
L1
L2
L3
L4
 40
 20
0
20
40
60
80
100
120
Primary Somatosensory Cortex (S) I contrast estimate
at [54,  12, 27]
L0
L1
L2
L3
L4
L0
L1
L2
L3
L4
 60
 40
 20
0
20
40
60
80
contrast estimate
at [6, 18, 42]
L0
L1
L2
L3
L4
L0
L1
L2
L3
L4
 40
 20
0
20
40
60
80
Posterior Cingular Cortex contrast estimate
at [6,  36, 24]
L0
L1
L2
L3
L4
L0
L1
L2
L3
L4
 20
 10
0
10
20
30
40
50
Supplementary Motor Area contrast estimate
at [6, 3, 63]
L0
L1
L2
L3
L4
L0
L1
L2
L3
L4
 60
 40
 20
0
20
40
60
80
L0
L1
L2
L3
L4
L0
L1
L2
L3
L4
1.5 0.5  0.5  1.5 0  1.5  0.5 0.5 1.5 0
OPRM1
118AA
OPRM1
118GG ٚ
  Results   
 
47 
3.2  Mu-opioid receptor expression and function in pain 
processing brain regions of non-carriers and carriers of 
OPRM1 118A>G SNP  
3.2.1  OPRM1 mRNA expression 
Analysis of the OPRM1 mRNA expression in relation to ACTB mRNA expression included sam-
ples of 12 non-carriers (118AA), 9 heterozygous carriers (118AG) and 3 homozygous carriers 
(118GG) of the OPRM1 118A>G SNP. OPRM1 mRNA expression was significantly lower in the  
SII-region  than  in  the  lateral  thalamus  (Factor  0.29  to  0.82;  rm-ANOVA  factor  “region”: 
F (1,21)=5.80, p=0.025; Figure 15 and Table 5). The 118A>G SNP had no significant influence 
on OPRM1 mRNA expression in both brain regions. 
Figure 15: OPRM1 mRNA expression. The expression was significantly lower in the SII-region than in the 
lateral thalamus. mRNA expression was unaffected by the 118A>G polymorphism (median/solid lines, 
mean/dashed lines, 5th and 95th percentiles/bars). 
 
 
 
0
2
4
6
8
10
12
SII Thal SII Thal SII Thal
118AA
(n=12)
O
P
R
M
1
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
[
2
]
 
(
C
t
)
∆
∆
118AG
(n=9)
118GG
(n=3)ٝ ㊐
  Results   
 
48 
Table 5: Summary of the descriptive data of the 46 post mortem human brain samples (Mean ± SEM). 
Test  Value  N  OPRM1  Region  Unit 
      118  SII  Thalamus   
OPRM1 mRNA 
expression 
2
-ΔΔCt 
12  AA  1.60 ± 0.48  2.78 ± 0.52 
-  9  AG  1.22 ± 0.17  2.75 ± 0.93 
3  GG  2.06 ± 0.39  4.89 ± 1.68 
[
3H]-DAMGO 
Saturation  
binding 
BMax([
3H]-DAMGO)  
18  AA  100.1 ± 8.90  156.5 ± 13.6 
fmol/mg of 
protein 
16  AG  112.2 ± 13.1  152.2 ± 16.9 
3  GG  136.5 ± 38.7  166.7 ± 69.3 
KD([
3H]-DAMGO) 
18  AA  2.1 ± 0.2  1.6 ± 0.3 
nM  16  AG  2.7 ± 0.4  1.8 ± 0.3 
3  GG  2.8 ± 0.8  1.6 ± 0.2 
[
3H]-DAMGO 
Displacement 
binding 
KI(Endorphine) 
14  AA  6.26 ± 2.00  - 
nM  7  AG  3.73 ± 1.06  - 
3  GG  4.19 ± 1.58  - 
KI(Methadone) 
14  AA  4.33 ± 0.61  - 
nM  7  AG  4.15 ± 0.88  - 
3  GG  4.49 ± 0.82  - 
KI(Morphine) 
14  AA  8.02 ± 0.81  - 
nM  7  AG  5.83 ± 0.91  - 
3  GG  7.37 ± 0.90  - 
KI(M6G) 
14  AA  17.72 ± 2.62  - 
nM  7  AG  13.43 ± 1.20  - 
3  GG  15.06 ± 1.24  - 
KI(Alfentanil) 
14  AA  25.19 ± 2.73  - 
nM  7  AG  16.86 ± 2.46  - 
3  GG  21.55 ± 6.01  - 
[
35S]-GTPγS 
binding 
B0(DAMGO) 
15  AA  1040.4 ± 95.0  963.4 ± 100.7 
fmol/mg of 
protein 
7  AG  819.9 ± 142.2  737.9 ± 187.7 
3  GG  724.8 ± 248.8  793.1 ± 180.1 
BMax(DAMGO) 
15  AA  1323.6 ± 112.9  1184.9 ± 108.9 
fmol/mg of 
protein 
7  AG  981.1 ± 165.0  1009.2 ± 222.3 
3  GG  956.6 ± 271.7  1164.3 ± 326.6 
BNet(DAMGO) 
15  AA  283.2 ± 42.7  221.4 ± 29.10 
fmol/mg of 
protein 
7  AG  161.1 ± 28.0  271.3 ± 71.70 
3  GG  231.9 ± 26.5  371.2 ± 156.5 
EC50(DAMGO) 
15  AA  1269.2 ± 371.3  262.2 ± 62.9 
nM  7  AG  637.5 ± 284.2  257.4 ± 29.2 
3  GG  1065.7 ± 750.7  130.1 ± 57.1 
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3.2.2  [3H]-DAMGO binding assays 
3.2.2.1  Saturation binding 
Analysis of the µ-opioid receptor protein expression (BMax) and the [
3H]-DAMGO equilibrium 
dissociation constant (KD) included samples of 18 carriers of 118AA, 16 carriers of 118AG and 3 
carriers of 118GG. Similarly to the OPRM1 mRNA expression, µ-opioid receptor protein expres-
sion was significantly lower in the SII-region than in the lateral thalamus (Factor 0.51 to 1.16; 
rm-ANOVA factor “region”: F (1,34)=9.19, p=0.005; Figure 16 and Table 5). The [
3H]-DAMGO 
equilibrium dissociation constant was significantly higher in the SII-region than in the thalamus 
(Factor 1.07 to 2.14; rm-ANOVA factor “region”: F (1,34)=8.88, p=0.005) indicating a lower 
affinity of [
3H]-DAMGO to µ-opioid receptors of the SII-region. However, the OPRM1 118A>G 
SNP had no significant effect on μ-opioid receptor expression and [
3H]-DAMGO equilibrium 
dissociation constant in both brain regions. 
Figure 16: Saturation binding. In line with OPRM1 mRNA expression, µ-opioid receptor expression was 
significantly lower in the SII-region than in the lateral thalamus. In addition, [
3H]-DAMGO had a lower 
affinity to µ-opioid receptors of the SII-region, indicated by a statistically significantly higher equilibrium 
dissociation constant (KD) of [
3H]-DAMGO. Receptor expression and affinity did not differ between carri-
ers and non-carriers of OPRM1 variant 118G (Nonlinear fit/solid and dashed lines, S.E.M/bars). 
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3.2.2.2  Displacement binding 
The following order of μ-opioid receptor affinities of the tested agonists was derived from the 
[
3H]-DAMGO independent inhibition constants (KI) determined in the SII-region of 14 carriers of 
118AA: β-endorphin ~ methadone > morphine > M6G > alfentanil (ANOVA factor “agonist”: 
F (4,105)=23.76, p<0.001; Figure 17 and Table 5). However, despite the ability to detect signifi-
cant differences in the KI-values between the different agonists, the OPRM1 genotype lacked 
significant  effects  on  the  [
3H]-DAMGO  independent  inhibition  constants,  although  the  ex-
pected magnitude of a potential genotype effect on the agonist-receptor-affinity would have 
been similar to the differences among the opioid receptor ligands. 
Figure 17: Displacement binding. Panel A presents displacement binding data of the unlabeled µ-opioid 
receptor agonists in the SII-region of 118AA carriers (n=14). Panel B1-5 presents displacement binding 
data of each agonist in carriers of OPRM1 118AA compared to that of 118AG and 118GG. The OPRM1 
118A>G had SNP had no significant effects on the affinity of the agonists in the SII-region (Nonlinear 
fit/solid, dashed and dotted lines, S.E.M/bars). 
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3.2.3  [35S]-GTPγS binding assays 
Analysis of the µ-opioid receptor signaling included brain samples of 15 carriers of 118AA, 7 
carriers of 118AG and 3 carriers of 118GG. Basal (B0) and maximum (BMax) [
35S]-GTPγS binding 
did not differ between both brain regions (Figure 18 and Table 5). In line with the lower affini-
ty of [
3H]-DAMGO in the SII-region, the DAMGO concentration needed to half-maximally stimu-
late the [
35S]-GTPγS binding (EC50) in the SII-region was significantly higher than needed in the 
thalamus (Factor 1.88 to 12.34; rm-ANOVA factor “region”: F (1,22)=10.26, p=0.004) indicating 
a lower potency of DAMGO to trigger µ-opioid receptor related intracellular G-protein signal-
ing in the SII-region. The genotype had no significant effects on any of the parameters. 
Figure 18: [
35S]-GTPγS binding. Basal and maximum [
35S]-GTPγS binding were similar in both brain re-
gions. In line with the lower affinity of [
3H]-DAMGO to μ-opioid receptors of SII, the potency of DAMGO 
to trigger µ-opioid receptor signaling was lower in SII than in the thalamus indicated by the significantly 
higher DAMGO concentration needed to stimulate half maximum [
35S]-GTPγS binding (EC50). The geno-
type had no significant effects on basal and maximum binding and EC50 (Nonlinear fit to mean of data 
/solid and dashed lines, S.E.M/bars).  
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hoc t-tests showed that non-carriers of the variant 118G allele had a 1.06 to 1.52 times higher 
net increase of [
35S]-GTPγS binding after DAMGO stimulation in the SII-region than in the lateral 
thalamus (t-test: t(14)=2.244, p=0.041). In contrast, no difference between brain regions was 
observed for heterozygous (Factor 0.39 to 0.95; t-test: t(6)=1.91, p=0.10, n=7) and homozyg-
ous (factor 0.39 to 1.20; t-test: t(2)=0.91, p=0.46, n=3) carriers of the variant 118G allele. 
Figure 19: Efficacy of DAMGO to stimulate [
35S]-GTPγS binding. Non-carriers of the variant 118G allele 
had a 1.06 to 1.52 times higher efficacy of DAMGO to stimulate G-protein signaling, measured as the net 
increase of [
35S]-GTPγS binding after DAMGO stimulation, in SII than in the thalamus. In contrast, differ-
ences between brain regions were absent in heterozygous and homozygous carriers of the variant 118G 
allele (median/solid line, mean/dotted line, 5th and 95th percentiles/bars; n.s. not significant, * p<.05). 
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p=0.36, n=7) and homozygous (Factor 0.66 to 1.15; t-test: t(2)=0.41, p=0.72, n=3) carriers of 
the variant 118G allele. 
Figure 20: Mu-opioid receptor expression related receptor signaling. While in non-carriers of OPRM1 
variant 118G the μ-opioid receptor-G-protein-coupling efficacy, measured as the DAMGO stimulated net 
increase of [
35S]-GTPγS binding per μ-opioid receptor, was significantly higher in the SII-region than in 
the lateral thalamus, it did not differ significantly between both brain regions in carriers of OPRM1 va-
riant 118G (median/solid line, mean/dotted line, 5th and 95th percentiles/bars; n.s. not significant, ** 
p<.01, *** p<.001). 
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3.3  Therapeutic range of alfentanil in carriers and non-carriers 
of OPRM1 118A>G SNP  
3.3.1  Plasma concentrations of alfentanil 
Target and measured alfentanil concentrations are plotted in Figure 21. Mean alfentanil plas-
ma concentrations at each level were not equal to target concentrations and subject to large 
interindividual variability. The target concentrations of 33.33 ng/ml were missed on average by 
-16 ± 4 percent, the target concentrations of 66.67 ng/ml were missed on average by 15 ± 5 
percent and the target concentrations of 100 ng/ml were missed on average by 20 ± 5 percent. 
However,  missing  of  the  target  concentration  did  not  jeopardize  the  pharmacokinetic-
pharmacodynamic analysis that related the effects to the actual individual alfentanil concen-
trations. The total amounts of administered alfentanil during the three levels of a total dura-
tion of approximately 195 min were 4.7 ± 0.3 mg for the 118AA group, 4.4 ± 0.5 mg for the 
118AG group and 5.8 ± 0.6 mg for the 118GG group. These different doses owe to the fact that 
a weight-adjusted alfentanil infusion was administered. The doses did not differ statistically 
significantly between genotype groups (Kruskal-Wallis test: p=0.5).  
Figure 21:  Study design, timing, target and measured alfentanil plasma concentrations. Measured 
alfentanil plasma concentrations of all subjects categorized in study groups (118AA, 118AG, 118GG) and 
associated mean plasma concentration of the group (thin colored lines). The solid black line represents 
target alfentanil effect site concentrations. Colored bars represent time-frames of experiments. Time 
zero is the start of the alfentanil infusion. 
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3.3.2  Analgesic effects of alfentanil 
Analgesia was indicated by the increase of tolerance versus electrical pain stimuli and the de-
crease of the CO2 pain stimuli rating with increasing alfentanil plasma concentrations (Figure 
22). The 95% confidence interval of the slope parameter a (Equation 1) never included zero. 
While the CO2 related pain ratings were best described by a power model (γ=0.394), data fits 
to the electrical pain stimuli test revealed a linear relationship between the alfentanil concen-
tration and analgesia (γ=1). The concentration-effect relationships of the main pharmacody-
namic measures are given in Table 7. By including a covariate θ1 (“genotype”) into the analysis 
of electrical pain stimuli test, fits to data improved statistically significantly for the combined 
groups 118AG and 118GG (p<0.05). Assigning two separate factors θ1 and θ2 to the slope of 
the concentration response relationship of groups 118AG and 118GG did not further improve 
the fits and heterozygous and homozygous carriers of the 118G variant allele were therefore 
not separated. As a result, heterozygous and homozygous carriers of the 118G allele variant 
needed a 2.2 times higher alfentanil concentration (167 ng/ml and 76 ng/ml for 118G carriers 
and non-carriers, respectively) to reach a 50% increase of analgesia above baseline in this pain 
model as compared to non-carriers.  
Similarly, the fits to data of the pain intensity of CO2-stimuli test improved statistically signifi-
cantly by including the covariate θ1 (“genotype”). But in contrast to the electrical pain model, 
fits improved only when assigning a factor θ to the slope of the concentration response rela-
tionship of the homozygous carriers of the 118G allele versus the combined groups 118AA and 
118AG (p<0.05). From the fits resulted that the required alfentanil concentrations to increase 
analgesia 50% above baseline, were multiplied by the factor 4.3 for the 118GG group (235 
ng/ml) as compared to the 118AA and 118AG group (55 ng/ml). Including a covariate “sex” 
into the analysis of the analgesic tests did not result in better fits to data.  
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Figure 22: Analgesia. (A) Electrical pain stimuli test: Population fit of the linear relationship between the 
alfentanil plasma concentrations and the increase of tolerance versus electrical pain stimuli. Fits to data 
improved by including a covariate θ1 (“genotype”) for combined groups 118AG and 118GG (p<0.05), 
indicating that both needed higher alfentanil plasma concentrations to reach same analgesia as 118AA 
group. (B) Pain intensity of CO2-stimuli test: Population fit of the relationship between the alfentanil 
plasma concentrations and the change in pain intensity ratings of the CO2-stimuli (duration 200 ms) 
delivered to the nasal mucosa. Including a covariate θ1 for genotype improved the population fits to 
data for the 118GG group (p<0.05), indicating that only the 118GG group needed higher alfentanil plas-
ma concentrations to reach the same analgesia as combined groups 118AA and 118AG in this test. 
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Table 7: Results of the population pharmacokinetic pharmacodynamic modeling relating the analgesic 
and respiratory depressive effects of alfentanil. Data is given as percent change from baseline, to its 
plasma concentrations by a power model (Equation 1). Complete model parameter values are given only 
for the final versions of the reduced and full models, i.e. of the models without and with implementa-
tion of the OPRM1 118A>G genotype. (#: Since no interindividual variability on the shape factor γ was 
observed as being a significant part of the models, the influence of the 118A>G SNP on the shape of the 
curve was not tested. %CV: percent coefficient of variation. CI: confidence interval. 2LL: minus two times 
the log-likelihood as goodness-of-fit measure. A change by 3.84 or 6.63 indicates a significance level of 
0.05 or 0.01, respectively, for the improvement of fit by introduction of one additional model parameter 
(likelihood-ratio test, on which the statistics was based in the present study [91]). 
 
Factor on a
# θ  2LL
Difference in
 2LL from
reduced model
Population
central value
(and 95% CI)
[%ng/ml]
Inter 
individualv
ariability
[%CV]
Population
central value
(and 95% CI)
[%ng/ml]
Inter 
individual
variability
[%CV]
Population
central value
(and 95% CI,
only for final
model)
reduced 0.45 79.3 1     1 443.438  
0.658
(0.412 0.911)
70.3 1  
θ1 on 118AG
and 118GG,
1 on 118AA
0.454
(0.167 0.809)
438.605  4.833
θ1 on 118GG,
1 on 118AA
and 118AG
Not given 440.713  2.725
θ1 on 118AG,
θ2 on 118GG,
1 on 118AA
Not given 438.528
 4.91, but only
 0.077 less from
only one θ
reduced 9.09 41.2 0.386       468.192  
θ1 on 118AG
and 118GG,
1 on 118AA
Not given 465.99  2.202
10.3
(4.7 19.2)
34.4 0.394  
θ1 on 118GG,
1 on 118AA
and 118AG
0.565
(0.310 0.951)
462.968  5.224
θ1 on 118AG,
θ2 on 118GG,
1 on 118AA
Not given
 5.233, but only
 0.009 less from
only one θ
reduced 8.37 57.8 0.34       442.887  
θ1 on 118AG
and 118GG,
1 on 118AA
Not given 437.822  5.065
10.5
(4.7 20.1)
39.6 0.35  
θ1 on 118GG,
1 on 118AA
and 118AG
0.416
(0.028 0.936)
433.482
 9.405,
 4.34 less than
previous
θ1 on 118AG,
θ2 on 118GG,
1 on 118AA
Not given 433.257
 9.63, but only
 0.225 less from
only one θ
reduced 0.907 95.3 0.626       380.318  
θ1 on 118AG
and 118GG,
1 on 118AA
Not given 375.745  4.573
1.3
(0.27 3.48)
73.6 0.64  
θ1 on 118GG,
1 on 118AA
and 118AG
0.222
(0.001 0.628)
371.455
 8.863,
 4.29 less than
previous
θ1 on 118AG,
θ2 on 118GG,
1 on 118AA
Not given 371.206
 9.112, but only
 0.249 less from
only one θ
Pharmaco 
dynamic
measure
Reduced
/full
model
Effect versus concentration relationship Role of the OPRM1 118A>G SNP
a γ
Pain intensity
of CO2 stimuli
full
Tolerance to
electrical pain
stimuli
full
Respiratory
frequency
full
Slope of the
VE versus
CO2
concentration
relationship full ٚ
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3.3.3  Respiratory depressive effects of alfentanil 
The slope of the relationship between the expiratory volume and CO2 concentration in the 
inspired air and the respiratory frequency decreased with increasing alfentanil plasma concen-
trations (Figure 23). The 95% confidence interval of the slope factor a (Equation 1) did not 
include  zero  (Table 7).  Data  of  both  experiments were  best  described  by  a  power model 
(γ=0.35 and γ=0.64, respectively).  
Including a covariate θ1 (“genotype”) significantly improved the fits to data for the 118GG 
group compared to the 118AA and 118AG groups in the CO2 re-breathing and the respiratory 
frequency test (p<0.01). Assigning two separate factors θ1 and θ2 to the slope of the concen-
tration response relationship of groups 118AG and 118GG or combining groups 118AG and GG 
worsened the fits. Therefore, a significant genotype effect could be established only for homo-
zygous carriers of the 118G variant allele. The analysis yielded a 12.3 times increase (1059 
ng/ml vs. 86 ng/ml for carriers of 118GG and 118AA/AG, respectively) and 10.5 times increase 
(3147 ng/ml vs. 300 ng/ml for carriers of 118GG and 118AA/AG, respectively) of the alfentanil 
concentration, respectively, to reach a 50% increase of the effect above baseline in the par-
ticular test. Including a covariate “sex” into the analysis of the applied tests did not result in 
better fits. 
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Figure 23: Respiratory depression. (A1-A4) Representative data of each a homozygous carrier of the 
118A and 118G allele, respectively, with similar age, sex and BMI. The build-up of the expiratory volume 
due to increasing end-tidal CO2 concentration is diminished with increasing alfentanil plasma concentra-
tions. The respiratory depression developed differently in the different OPRM1 genotypes with respect 
to cDNA position 118. Inserts: Raw data of respiratory frequency test: Associated raw data of the respi-
ratory frequency test. (B1) Relative change of the slope of the linear relationship between the expiratory 
volume and end-tidal CO2 concentration with increasing alfentanil plasma concentrations. (B2) Relative 
change of the respiratory frequency with increasing alfentanil plasma concentrations. The inclusion of 
the covariate θ1 for genotype significantly improved the fit to data for the 118GG (p<0.01). Data are 
shown as relative decrease in percent ± SEM of baseline. Solid and dashed lines represent the popula-
tion fits to the data. 
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4  Discussion 
Based on the findings that SNP OPRM1 118A>G diminishes opioid analgesia, we hypothesized 
that SNP OPRM1 118A>G will result in a modification of the concentration-dependent effect of 
opioids in brain areas involved in pain processing. To analyze the underlying mechanism, we 
identified pain processing brain regions in healthy non-carriers of SNP OPRM1 118A>G, which 
showed a reduction of pain related activation with increasing alfentanil concentrations, and 
analyzed the concentration-effect relationship of alfentanil in these areas. Subsequently, we 
analyzed in a second step, whether SNP OPRM1 118A>G alters the concentration-effect rela-
tionship of alfentanil in pain processing brain areas of homozygous OPRM1 118A>G carriers. 
We observed brain activation in response to specific nociceptive trigeminal stimulation in re-
gions repeatedly reported to be involved in the processing of pain [6, 9]. Analysis of opioid 
effects on the activation in these pain-relevant regions revealed a dual pattern of concentra-
tion-dependent and concentration-independent effects.  
Concentration-dependent alfentanil effects were seen in the primary (SI) and secondary (SII) 
somatosensory cortex and posterior parts of the insula. These regions are known to be mainly 
associated with processing of the sensory intensity of pain [7, 69, 94-96]. Our results corres-
pond to a linear relationship between pain-intensity and activation in the secondary somato-
sensory cortex SII and the posterior insula [97], indicating that these regions reflect the opioid-
induced decrease of the sensory dimension of pain.  
In contrast, concentration-independent behavior was observed in the parahippocampal gyrus, 
the amygdala and anterior parts of the insula. These regions are known to be mainly involved 
in circuits processing the affective dimension of pain [59, 98-101]. In these regions, the pain-
associated  activation  disappeared  already  at  the  lowest  alfentanil  concentration  (level  1, 
19.6±2.7 ng/ml), but subjects still perceived pain not significantly differently from baseline. 
Thus, the present observation provides a fMRI correlate for the previous observation that very 
low doses of morphine (0.04-0.06 mg/kg) significantly reduced the affective but not the sen-
sory component of painful heat stimuli [102].  
Thus, we observed that (i) pain-associated activation decreased linearly with increasing alfen-
tanil concentrations in brain regions known to process the sensory intensity of pain [97], and 
that (ii) pain-associated activation disappeared at low opioid concentrations in regions known 
to process the affective components of pain. The demonstrated dual effect of opioids on pain-沀٣
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associated brain activation may provide a neuroscientific basis for their use in pain treatment 
as advised by the WHO. On the one hand, low doses of opioids, which are not accompanied by 
opioid side effects, may indeed enhance non-opioid analgesia by reducing the affective dimen-
sions of pain (WHO Step 2). On the other hand, our results indicate that opioid analgesia does 
not reach a plateau and that an increase in opioid dose as advised in WHO step 3 may indeed 
be expected to further reduce the intensity of pain.  
The intermediate decrease of pain-associated brain activation, i.e. the neither clearly concen-
tration-dependent nor clearly concentration independent, is in line with the hypothesis of dual 
opioid effects on sensory and affective dimensions of pain because it was observed in brain 
regions involved in the integrative processing of both sensory and affective nociceptive infor-
mation such as the insular cortex [7, 9, 69, 96, 99], which due to this dual involvement has 
been proposed to be an integrative region for both dimensions [100]. It further applies to the 
anterior cingulate cortex, which similarly has been proposed as a multi-integrative structure of 
stimulus perception and affective and attentional processing of pain [6, 9, 103]. Due to this 
integrative processing in the presence of high opioid receptor densities [20, 104], both regions 
seem to be of high significance in central nervous opioid analgesia [105].  
The hypothesized modification of the concentration-dependent opioid effects of alfentanil by 
SNP  OPRM1  118A>G  was  mainly  observed  in  brain  regions  that  showed  linear  alfentanil-
concentration dependent decreases in pain related brain activation and that are known to be 
part of the circuit processing sensory components pain. This is in line with the repeatedly ob-
served decrease of opioid analgesia in experimental pain [65, 106] and decrease of opioid-
induced miosis [47, 49, 107] in carriers of SNP OPRM1 118A>G. It suggests that the increased 
opioid requirements by pain patients who carry SNP OPRM1 118A>G [43, 44] are mainly due to 
the decreased reduction of the sensory intensity of pain. On the other hand, the results sug-
gest that in the context of pain therapy, SNP OPRM1 118A>G is less likely to modulate affectiv-
ity as it has been suggested due to its association with substance addiction [53]. The more 
pronounced effects of SNP OPRM1 118A>G in regions associated with processing the sensory 
rather than the affective dimension of pain are also reflected in its functional associations, 
which are predominantly positive in the context of pain therapy while its functional associa-
tions in the context of addiction are more controversial (for review, see [36]).  
Based on the fMRI findings that SNP OPRM1 118A>G affects primarily brain regions processing 
the sensory information of pain, the molecular mechanism of the SNP OPRM1 118A>G was 沀٣
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investigated in post mortem samples from the human SII region. In addition, a sample from the 
ventral posterior part of the lateral thalamus, a region involved in the transmission of nocicep-
tive information to the SII region, was selected to serve as a control region that should be unaf-
fected by the SNP OPRM1 118A>G.  
On the molecular level, the brain-region specificity of the consequences of the ORPM1 118A>G 
polymorphism, which had been suggested by fMRI analysis of alfentanil analgesia [108] but 
had been neglected in the region-unspecific assessments of its consequences in human brain 
tissue [109] and for methodological reasons in all transfection experiments with cell lines not 
originating from human brain [37-39, 109, 110], was presently found to be the main effect of 
this genetic variant. The ORPM1 118A>G polymorphism appears to modulate the regional dif-
ferences  of DAMGO  efficacy  to  stimulate G-protein  binding.  Due  to  the more  efficient  G-
protein coupling, DAMGO was significantly more effective in G-Protein activation in SII than in 
the thalamus of non-carriers of the 118G variant allele. This regional specificity was lost in car-
riers of the 118G variant, where G-Protein activation in SII was equal to that in the thalamus. 
Thus, although the effects of OPRM1 118A>G seem to be regionally limited, the genetic variant 
appears to interfere with the connectivity of brain regions of the pain processing network. In 
contrast to former reports investigating OPRM1 118A>G SNP effects in transfected cell cul-
tures, the results are gained from a random sample of human brain regions known to be im-
portant for pain transmission and processing. Thus, they are more likely to reflect the clinical 
context and provide for the first time a molecular correlate for the repeatedly and consistently 
reported decreased opioid effects in carriers of the µ-opioid receptor variant N40D.  
In accordance to the fMRI results, the reduction of µ-opioid receptor signalling efficacy being 
observed much more in SII than in the thalamus suggests that the 118A>G variant mainly 
modulates the subjective perception of nociceptive input rather than its transmission. Activa-
tion of SII, posterior parts of the insula and the thalamus is known to correlate with the subjec-
tive perception of pain intensity [7, 97] and opioids such as remifentanil have been shown to 
diminish pain-related activation of SII and the thalamus, which coincided with a decrease of the 
subjective pain intensity perception [111]. Thus, the present findings indicate that an impor-
tant role in the reduced pain relief after opioid administration to carriers of the variant 118G 
as compared to non-carriers [43-46, 65] plays a decreased µ-opioid receptor signalling in SII 
relative to that in the thalamus. It is likely that other brain regions are also differently affected, 
and based on the present results, future investigations may provide a more complete topogra-
phy of the brain regions affected by the clinically functional OPRM1 118A>G variant.  沀٣
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Although receptor expression assessed twice by saturation binding and by mRNA quantifica-
tion was significantly higher in the thalamus than in SII, we could not reproduce a genotype 
difference in receptor expression levels [109]. This might again relate to the here proposed 
brain region specificity of the N40D consequences. The previously observed decreased expres-
sion might be limited to the pons and to the not further specified, possibly pooled cortical ar-
eas [109]. The brain region specificity of the N40D consequences makes receptor expression 
an unlikely general molecular basis of reduced analgesia in carriers of OPRM1 variant 118G. In 
fact, this expression consequences have been observed so far in brain regions [6] not directly 
involved in pain perception [109], or in non-brain and non-human cell lines [38, 39, 110]. On 
the other hand, not related to the OPRM1 118A>G variant, regionally limited alterations of µ-
opioid receptor expression have already been shown for other SNPs known to affect the opioid 
system such as the COMT 472G>A [112, 113]. This makes previous results of reduced brain µ-
opioid receptor expression in other regions possible for the N40D variant [109] and thus does 
not dispute those results, but at the same time, it strengthens our conclusion that a µ-opioid 
receptor genetic variant can have brain-region specific effects, presently mainly found at a 
receptor signalling rather than expression level.  
Further support for an effect of the N40D variant on the interaction between brain regions 
rather than on opioid effects within a single region is provided by the findings that although µ-
opioid receptors of both brain regions differed in their affinity to DAMGO, they were unaf-
fected by the OPRM1 118A>G SNP, and the µ-opioid receptor affinity of β-endorphin in the SII 
region of non-carriers and carriers of OPRM1 variant 118G was similar. The similar β-endorphin 
affinity disagrees with the reported three-times higher binding affinity of human β-endorphin 
to N40D variant µ-opioid receptor transfected AV-12 cells [37] but agrees with all other publi-
cations [38, 39, 110]. Also agreeing with most publications [38, 39, 110], the affinity of other 
opioids associated with decreased effectiveness in carriers of OPRM1 variant 118G [43-47, 65, 
107] was also unaffected by the OPRM1 118A>G SNP. Thus, a general decrease of the affinity 
of µ-opioid receptor agonists to N40D variant receptors is unlikely to be the cause of the re-
duced opioid effectiveness in carriers of OPRM1 variant 118G. 
Additional investigations will be necessary to finally uncover the brain region specific modula-
tion of µ-opioid receptor signalling by the OPRM1 118A>G polymorphism as we cannot provide 
a clear mechanism of how the OPRM1 118A>G SNP diminishes µ-opioid receptor signalling. 
However, our results clearly demonstrate the advantages of brain region specific analysis of µ-
opioid  receptor  binding  and  signalling  characteristics  in  human  brain  tissue  compared  to 沀٣
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OPRM1 transfected cell cultures. The importance of brain-region dependent variable expres-
sion and function of opioid receptors [20, 21, 83, 114] for the functional consequences of the 
OPRM1 118A>G SNP might be the major reason for failed or contradictory investigations of its 
function in cell cultures sharply contrasting to the consistent clinical findings of decreased 
opioid effects in carriers of variant 118G [43-47, 65, 107]. To which extent region-specific ex-
pression of µ-opioid receptor splice variants and coupling to Gα and Gβγ subunits, which is 
known to influence µ-opioid receptor signalling [115-118], contribute to the brain region de-
pendent effects of the N40D variant, may be addressed in the future. 
Last but not least, we addressed the problem of whether both, analgesic and respiratory de-
pressive, effects are decreased in the presence of the OPRM1 118A>G SNP or whether this 
genetic variant decreases only the analgesic effects of opioids. This issue has major clinical 
implications. If the first is true, opioid doses may be safely increased to achieve adequate anal-
gesia in carriers of the 118G variant allele. In contrast, if the second alternative is true, increas-
ing the opioid doses to produce adequate analgesia would put the patients at risk for respira-
tory depression being the most dangerous opioid side effect. Results of previous investigations 
supported both alternatives. A protective effect of the 118G variant against opioid toxicity was 
hypothesized  from  the  good  tolerance  of  high  plasma  concentrations  of  morphine-6-
glucuronide by a homozygous carrier of the 118G allele [36] and from the rarer occurrence of 
vomiting  in  carriers  of  the  118G  allele  after  administration  of  high  doses  of  morphine-6-
glucuronide [47]. To this sharply contrasts a report of similar respiratory depression despite 
lower  analgesia  produced  by  morphine-6-glucuronide  in  four  heterozygous  carriers  of  the 
118G allele as compared to 12 non-carriers of the variant [46], which suggests a narrowed 
therapeutic range of opioids in carriers of the 118G variant allele.  
We demonstrate that the OPRM1 118A>G SNP results in a broadened therapeutic range of 
alfentanil in healthy homozygous carriers. Analysis of the effect versus concentration relation-
ship showed that higher opioid concentrations are needed to achieve analgesia in 118GG car-
riers, a result which is in line with previous findings [43, 45-47, 107]. However, the required 
increase in opioid dosing appears to be safe because it does not increase the risk for respirato-
ry depression. In contrast, based on the pharmacodynamic model (Equation 1) with the esti-
mated parameters given in Table 7, when calculating the alfentanil concentrations needed to 
provide a 50% increase of the pain tolerance threshold to electrical pain or a 50% increase in 
the pain intensity of the CO2 stimuli, 2 – 4 times higher alfentanil concentrations are sufficient 
to produce the same degree of analgesia in subjects with an OPRM1 118GG genotype as in 沀٣
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subjects not carrying this particular genotype. In contrast, 10 – 12 times higher alfentanil con-
centrations are needed to produce the same degree of respiratory depression in subjects with 
an OPRM1 118GG as in subjects not carrying this genotype. This is compatible with a broa-
dened therapeutic range of opioids in healthy homozygous carriers of the OPRM1 118G variant 
allele. Thus, increasing the opioid dose in homozygous 118G carriers to achieve adequate anal-
gesia is probably clinically safe. This consequence could not be observed by Romberg et al. [46] 
because that study did not include homozygous carriers of the 118G allele.  
Heterozygous carriers of the 118G allele were recruited to substitute for the lacking of four 
homozygous carriers to match the ten healthy controls. Due to the smaller sample size, the 
results for the heterozygous subjects are of lower confidence level compared to those of the 
homozygous subjects. Nonetheless, with respect to healthy heterozygous carriers of the 118G 
variant allele, our result supports the previously observed lack of a protective effect of the 
118G allele against opioid-induced respiratory depression despite reduced analgesic response 
[46]. Thus, it appears that caution has to be exercised in subjects who heterozygously carry the 
OPRM1 118G allele when raising the opioid dose in order to produce adequate pain relief. 
Dependently on the type of pain, opioid analgesia appears to be differently affected in hetero-
zygous carriers of the 118G allele. To produce analgesia, they needed higher alfentanil concen-
trations than wild-type subjects only in the electrical pain test but not in the CO2 pain model, 
emphasizing that the gene-dose effect of the 118G allele may differ among pain qualities. In 
contrast to homozygous carriers of the OPRM1 118G variant allele, a similar dosing advice for 
heterozygous carriers of the OPRM1 118G allele is therefore not possible. First, a decreased 
opioid potency to produce analgesia does not appear to apply to all kinds of pain. Therefore, a 
dose increase may not be generally required in pain therapy in heterozygous 118G carriers. 
Second, if inadequate relief of particular qualities of pain requires a dose increase, this may be 
associated with an increased risk for respiratory depression. Therefore, present evidence to-
gether with a similar previous finding [46] does not allow to emit an opioid dosing advice for 
heterozygous 118G carriers. In addition, the number of four heterozygous carriers of the va-
riant 118G allele is lower than that of the six homozygous carriers, which further weakens dos-
ing recommendations based on the present study results. Nonetheless, the central tendency of 
respiratory depression parameters found with heterozygous 118G carriers was similar to that 
found with wild-type controls and did not lay between genotypes 118AA and 118GG. Thus the 
present data contain no strong suggestion that with a greater number of 118AG carriers a sta-沀٣
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tistical significance could have been easily reached for the difference between 118AA and 
118AG carriers.  
We observed a tendency toward less frequent vomiting in carriers of the 118G allele, but in 
contrast to a previous study [47] this did not reach statistical significance. A reason for this 
may be the comparatively lower opioid doses in the present study. While the administered 
alfentanil doses were high enough to trigger opioid side-effects including vomiting, judged by 
the overall side effects the opioid effects were much lower than the previous effects of mor-
phine-6-glucuronide [47]. This interpretation concurs with other studies with comparatively 
lower opioid effects [49], where also the number of vomits did not significantly differ between 
carriers and non-carriers of SNP OPRM1 118A>G. This suggests that the 118A>G polymor-
phisms is not the only factor for opioid induced vomiting and other causes have to be ad-
dressed in separate studies focused on that particular side effect. 
Although we interpret our results in a clinical context for a possible opioid dosing, great cau-
tion has to be exercised when applying the findings into clinical practice. On the one hand, our 
laboratory setting is quite distinct from the clinical setting of intra- and postoperative opioid 
analgesia. The subjects were healthy volunteers, who did not receive any co-medication to 
alfentanil, which differs from the perioperative medication where additive respiratory depres-
sant drug interactions may occur. Also, we assessed experimental pain rather than clinical 
pain. Moreover, respiratory depression depends on the subjects arousal [119], a further differ-
ence between the present study and the clinical situation. Furthermore, the present estimates 
of therapeutic range are extrapolations from the obtained numerical results and the used 
pharmacodynamic model, which, as any extrapolation, demands great caution when applying 
it to another context. Despite these limitations, the present study provides a defined hypothe-
sis of the consequences of the OPRM1 118A>G polymorphisms for wanted and unwanted ef-
fects  of  alfentanil  for  future  clinical  studies,  which  should  evaluate  the  usefulness  of  the 
present findings for clinical therapy and may re-evaluate the question of heterozygous subjects 
in a greater number of participants. 沀٣
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5  Conclusion 
In conclusion, the data demonstrate that the OPRM1 118A>G SNP primarily diminishes opioid 
effects on pain related brain activation in brain regions processing the sensory dimension of 
pain, which is in line with the repeatedly observed decrease of opioid analgesia in experimen-
tal pain and decrease of opioid-induced miosis in carriers of SNP OPRM1 118A>G. In contrast, 
regions processing the affective dimension of pain were unaffected by this receptor variant.  
On the molecular level, this brain region-specific effect of SNP OPRM1 118A>G seems to result 
from a brain region-dependent modulation of µ-opioid receptor signalling by OPRM1 118A>G 
SNP. While the variant has no effects on µ-opioid receptor signalling in the lateral thalamus, it 
abolishes the increased µ-opioid receptor signalling efficacy in the SII-region relative to that in 
the thalamus. Considering that SII is a region that codes for pain intensity, these results provide 
a molecular correlate for the observed decrease of opioid effects in brain regions processing 
the sensory dimension of pain and the decreased potency of opioids to reduce the subjective 
pain intensity in carriers of the OPRM1 variant 118G.  
In addition, the data confirm the hypothesis that the SNP OPRM1 118A>G affects both the 
analgesic and respiratory depressive effects of alfentanil. However, while the analgesic effects 
are partly already decreased in heterozygous carriers, depending on the pain model, the respi-
ratory depressive effects are decreased only in homozygous carriers of the variant 118G allele. 
Moreover, the therapeutic range of alfentanil was broadened in homozygous carriers, which is 
further evidence for the brain region-dependent effects of the OPRM1 118A>G SNP. Thus, the 
results demonstrate that the OPRM1 polymorphism 118A>G protects against opioid-induced 
respiratory depression in homozygous carriers, whereas it does not seem to protect against 
opioid-induced  respiratory  depression  in  heterozygous  carriers,  despite  reduced  analgesic 
response in some kinds of pain.  
As a consequence, these results introduce the brain-region specificity and interregional com-
parisons as important new components into analyses of the genetic modulation of the human 
opioid system, and they provide a solid basis for continuing investigations in larger study popu-
lations of patients to address the role of OPRM1 118A>G genotyping for pain therapy in the 
clinical context. 沀٣
  Abstract   
 
68 
6  Abstract 
The µ-opioid receptor is the primary target structure of most opioid analgesics and thus re-
sponsible for the predominant part of their wanted and unwanted effects. Carriers of the fre-
quent genetic µ-opioid receptor variant N40D (allelic frequency 8.2 - 17 %), coded by the single 
nucleotide polymorphism A>G at position 118 of the µ-opioid receptor coding gene OPRM1 
(OPRM1 118A>G SNP), suffer from a decreased opioid potency and from a higher need of opio-
id analgesics to reach adequate analgesia. The aim of the present work was to identify the 
mechanism by which the OPRM1 118A>G SNP decreases the opioid potency and to quantify its 
effects on the analgesic potency and therapeutic range of opioid analgesics. 
To elucidate the consequences of the OPRM1 118A>G SNP for the effects of opioid analgesics, 
brain regions of healthy homozygous carriers of the OPRM1 118A>G SNP were identified by 
means of functional magnetic resonace imaging (fMRI), where the variant alters the response 
to opioid analgesics after painful stimulation. Afterwards, the µ-opioid receptor function was 
analyzed on a molecular level in post mortem samples of these brain regions. Finally, the con-
sequences of the OPRM1 118A>G SNP for the analgesic and respiratory depressive effects of 
opioids were quantified in healthy carriers and non-carriers of OPRM1 118A>G SNP by means 
of experimental pain- and respiratory depression-models. 
To identify pain processing brain regions, where the variant alters the response to opioid anal-
gesics after painful stimulation, we investigated the effects of different alfentanil concentra-
tion levels (0, 25, 50 and 75 ng/ml) on pain-related brain activation achieved by short pulses 
(300 msec) of gaseous CO2 (66% v/v) delivered to the nasal mucosa using a 3.0 T magnetic 
head scanner in 16 non-carriers and nine homozygous carriers of the µ-opioid receptor gene 
variant OPRM1 118A>G. In brain regions associated with the processing of the sensory dimen-
sion of pain (pain intensity), such as the primary and secondary somatosensory cortices and 
the posterior insular cortex, the activation decreased linearly in relation to alfentanil concen-
trations, which was significantly less pronounced in OPRM1 118G carriers. In contrast, in brain 
regions known to process the affective dimension of pain (emotional dimension), such as the 
parahippocampal gyrus, amygdala and anterior insula, the pain-related activation disappeared 
already at the lowest alfentanil dose, without genotype differences.  
Subsequently, we investigated the µ-opioid receptor-expression ([
3H]-DAMGO saturation ex-
periments,  OPRM1  mRNA  analysis  by  means  of  RT-PCR),    the  µ-opioid  receptor  affinity  
([
3H]-DAMGO saturation and competition experiments) and µ-opioid receptor signaling ([
35S]-沀٣
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GTPγS binding experiments) in post mortem samples of the human SII-region, as a cortical pro-
jection region coding for pain intensity, and lateral thalamus, as an important region for noci-
ceptive transmission. Samples of 22 non-carriers, 21 heterozygous and three homozygous car-
riers of OPRM1 118A>G SNP were included into the analysis. The receptor expression and re-
ceptor affinity of both brain regions did not differ between non-carriers and carriers of the 
variant N40D. In non-carriers, the µ-opioid receptors of the SII-region activated the receptor 
bound G-protein more efficiently than those of the thalamus (factor 1.55-2.27). This regional 
difference was missing in heterozygous (factor 0.78-1.66) and homozygous (factor 0.66-1.15) 
carriers of the N40D variant indicating a reduced receptor-G-protein-coupling in the SII-region.  
Finally, the consequences of the alteration of µ-opioid receptor function in carriers and non-
carriers of the genetic variant was investigated using pain- and respiratory depression-models. 
Therefore, 10 healthy non-carriers, four heterozygous and six homozygous carriers of the µ-
opioid receptor variant N40D received an infusion of four different concentrations of alfentanil 
(0, 33.33, 66.66 and 100 ng/ml). At each concentration level, analgesia was assessed by means 
of electrically (5 Hz sinus 0 to 20 mA) and chemically (200 ms gaseous CO2 pulses applied to the 
nasal mucosa) induced pain, and respiratory depression was quantified by means of hypercap-
nic challenge according to Read and recording of the breathing frequency. The results showed 
that depending on the used pain model, both heterozygous and homozygous carriers of the 
variant N40D needed 2 – 4 times higher alfentanil concentrations to achieve the same analge-
sia as non-carriers. This increase seems to be at least for homozygous carriers unproblematic, 
because to reach a comparable respiratory depression as non-carriers, they needed 10-12 
times higher alfentanil concentrations. 
The results of this work demonstrate that the µ-opioid receptor variant N40D causes a regio-
nally limited reduction of the signal transduction efficiency of µ-opioid receptors in brain re-
gions involved in pain processing. Thus, the painful activation of sensory brain regions coding 
for pain intensity is not sufficiently suppressed by opioid analgesics in carriers of the variant 
N40D. Due to the insufficient suppression in hetero- and homozygous carriers of the variant 
N40D, the concentration of opioids has to be increased by a factor 2 - 4, in order to achieve the 
same analgesia as in non-carriers. At the same time, the respiratory depressive effects are 
decreased to a greater extent in homozygous carriers of the N40D variant as they need a 10 - 
12 times higher opioid concentration to suffer from the same degree of respiratory depression 
as non-carriers. Due to the increased therapeutic range of opioid analgesics, an increase of the 
opioid dose seems to be harmless, at least for homozygous carriers of the N40D variant. 沀 ჶ ٣
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7  Deutsche Zusammenfassung 
Opioidanalgetika sind bis heute das adäquate Mittel zur Behandlung schwerer Schmerzzustän-
de. Dabei wird ihre breite Anwendbarkeit durch opioidtypische unerwünschte Nebenwirkun-
gen wie Atemdepression, Benommenheit, Übelkeit bis zum Erbrechen, Obstipation, Miosis und 
juckende Hautreizung eingeschränkt. Das Ausmaß der auftretenden Opioidwirkungen variiert 
von Patient zu Patient. Fortschritte in der genetischen Forschung haben gezeigt, dass ein Teil 
der Variabilität von Opioidwirkungen in der genetischen Variabilität der Bevölkerung begrün-
det liegt.  
Opioide wirken über G-Protein-gekoppelte Rezeptoren, die Opioidrezeptoren, bestehend aus 
dem μ-, κ-, δ-Opioidrezeptor. Anhand von μ-Opioidrezeptor-Knockout-Mäusen konnte gezeigt 
werden, dass vor allem die μ-Opioidrezeptoren für den überwiegenden Teil der erwünschten 
und  unerwünschten  Wirkungen  von  Opioidanalgetika  verantwortlich  sind.  Die  μ-Opioid-
rezeptoren werden vom OPRM1 Gen codiert. Bei einer häufigen genetischen Variante des μ-
Opioidrezeptor-Gens OPRM1 (Allelfrequenz ca. 8,2-17%) steht an Position 118 in Exon 1 das 
Nukleotid Adenin anstatt Guanin (OPRM1-118A>G-Polymorphismus). Als Folge wird anstelle 
von Asparagin die Aminosäure Aspartat an Position 40 (N40D) der N-terminalen extrazellulä-
ren Rezeptorbindungsdomäne eingebaut.  
Bei Trägern der μ-Opioidrezeptor-Variante N40D wurde wiederholt eine Verminderung der 
Opioidpotenz und ein erhöhter Bedarf von Opioidanalgetika zur adäquaten Schmerzstillung im 
Vergleich zu Nichtträgern der Variante beobachtet. Desweiteren weisen einige Studien auf 
eine Erhöhung der therapeutischen Breite von Opioidanalgetika in Trägern dieser Variante hin. 
So benötigten Träger der N40D Variante im Vergleich zu Nichtträgern höhere Konzentrationen 
von Alfentanil (1,3-fach) bzw. Morphin (2-fach), um die gleiche Analgesie bei postoperativen 
Schmerzen zu erreichen, und dennoch waren sie weniger von opioidtypischen unerwünschten 
Wirkungen betroffen. Die miotischen Effekte von Morphin, seines aktiven Metaboliten Mor-
phin-6-glucuronid (M6G) und Levomethadon waren in Trägern der N40D Variante verringert 
und Träger des varianten Allels mussten nach hohen Dosen M6G weniger erbrechen als Nicht-
träger. Es gibt aber auch eine Studie, deren Ergebnisse gegen eine erhöhte therapeutische 
Breite von Opioiden in Träger des varianten 118G-Allels sprechen. Diese zeigte, dass in hetero-
zygoten Trägern des 118G Allels die Analgesie nach M6G Gabe zwar verringert war, die atem-
depressiven Effekte von M6G aber unverändert waren. Dies deutet auf eine verminderte the-
rapeutische Breite von Opioiden in heterozygoten Trägern hin.  貀٣ 
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Die der verminderten Opioidpotenz zu Grunde liegenden molekularen Mechanismen sind nicht 
eindeutig  geklärt.  So  wurde  in  AV-12-Zellen,  die  mit  der  118G  Variante  des  
µ-Opioidrezeptor-Gens transfiziert wurden, eine 3-fach höhere Affinität des N40D Rezeptors zu 
seinem endogenen Liganden β-Endorphin beobachtet, während die Affinität zu Opioiden wie 
Morphin oder dessen aktiven Metaboliten Morphin-6-glucuronid unverändert waren. Diese 
Ergebnisse erklären leider nicht die verminderte Opioidpotenz bei Trägern der 118G Variante. 
Eine mögliche Erklärung für die verminderte Opioidanalgesie wäre eine verminderte Rezepto-
rexpression in Trägern der 118G Variante. Die Möglichkeit einer verminderten Rezeptorexp-
ression wird durch die Beobachtung gestützt, dass in Hirngewebsproben von Trägern der 118G 
Variante im Vergleich zu Nichtträgern tendenziell geringere Mengen an OPRM1 mRNA gefun-
den wurden, was auf eine verminderte Expression des Rezeptorproteins hinweisen könnte. 
Diese  Vermutung  wird  durch  Ergebnisse  aus  Rezeptorexpressions-Experimenten  in  mit  der 
118G Variante des µ-Opioidrezeptor-Gens transfizierten HEK 293-Zellen und CHO-Zellen un-
termauert. Im Gegensatz dazu gibt es auch Veröffentlichungen, in denen die Rezeptorexpres-
sion in mit der 118G Variante transfizierten HEK 293-Zellen und COS-Zellen unverändert war. 
Daher ist der endgültige Beweis, dass die µ-Opioidrezeptorexpression in Trägern der 118G 
Variante verringert ist, noch nicht erbracht.  
Die genau Bestimmung der Folgen der OPRM1 118A>G Mutation für die Potenz und therapeu-
tische Breite von Opioidanalgetika ist für eine effektive und sichere Schmerztherapie bei Trä-
gern des varianten 118G-Allels von größtem Interesse. Auch der molekulare Mechanismus, der 
der verminderten Opioidwirkung in Trägern des OPRM1 118A>G SNP zu Grunde liegt, kann 
nicht als endgültig geklärt betrachtet werden. Ziel dieser Arbeit war es daher, den Mechanis-
mus zu identifizieren, der zu der Verminderung der Opioidpotenz und einem erhöhten Ver-
brauch von Opioidanalgetika in Trägern der µ-Opioidrezeptor-Variante N40D führt. Außerdem 
sollten die Auswirkungen auf die analgetische Wirkung und therapeutische Breite von Opioi-
danalgetika in Trägern der µ-Opioidrezeptor-Variante N40D untersucht werden.  
Zur Aufklärung der Auswirkungen der N40D-Variante auf die Opioidwirkungen wurden mittels 
funktioneller  Bildgebung  diejenigen  Hirnregionen  identifiziert,  in  denen  sich  der  OPRM1-
118A>G-Genotyp auf die Schmerzverarbeitung auswirkt. Anschließend wurde die Opioidrezep-
tor-Signaltransduktion in post-mortem gewonnenen Proben aus diesen Hirnregionen mittels 
molekularbiologischer Methoden analysiert. Schließlich wurden die Auswirkungen dieser Ver-
änderungen für Träger der Variante N40D anhand pharmakodynamischer Schmerz- und Atem-
depressionsmodelle untersucht. 貀٣
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Im ersten Schritt wurde in einer klinischen Studie die Dosis-Wirkungsbeziehung von Alfentanil 
in schmerzverarbeitenden Hirnregionen von Nichtträgern und Trägern der N40D Variante un-
tersucht. Hierdurch wurden Zielstrukturen im Gehirn identifiziert, die an der Schmerzverarbei-
tung beteiligt sind und in denen die schmerzbezogene Aktivierung nach Opioidapplikation bei 
Trägern der N40D Variante verändert ist. Dazu wurden 16 gesunden Nichtträgern und 9 homo-
zygoten Trägern der OPRM1 Variante 118G mittels computerisierter Infusion vier verschiedene 
Konzentrationen des schnell wirksamen Opioids Alfenanil infundiert, um Zielkonzentrationen 
am Wirkort (ZNS) von 0, 25, 50 und 75 ng/ml einzustellen. Mit Hilfe eines Magnetresonanzto-
mographen (3.0T) und der dadurch möglichen funktionellen Bildgebung (fMRT) wurde bei je-
der Zielkonzentration die schmerzkorrelierte Hirnaktivierung nach schmerzhafter chemischer 
Stimulation der Nasenschleimhaut durch kurze Reize gasförmigen CO2 (66% v/v; Reizdauer 
300ms) gemessen. Die an der Schmerzverarbeitung beteiligten Hirnregionen waren durch auf-
steigende Alfentanilkonzentrationen unterschiedlich betroffen: An der Verarbeitung der sen-
sorischen Schmerzkomponente beteiligte Hirnregionen, wie z.B. der primäre und sekundäre 
somatosensorische Cortex (SI und SII), zeigten eine von der Konzentration linear abhängige 
Abnahme der schmerzreiz-assoziierten Aktivierung, welche statistisch signifikant geringer in 
homozygoten Trägern der 118G Variante war. In die Verarbeitung der affektiven Schmerzkom-
ponente involvierte Regionen, wie z.B. die Amygdala, zeigten dagegen bereits bei der niedrigs-
ten Alfentanilkonzentration eine abrupte, nicht-lineare, stufenförmige Abnahme der schmerz-
reiz-assoziierten Aktivierung. Diese Hirnregionen waren nicht von der Mutation betroffen. Die 
Ergebnisse zeigen damit eine dosisabhängige Dissoziation von Opioidwirkungen auf die affekti-
ve und sensorische Dimension von Schmerzen. Dabei stellt die verringerte Wirkung von Alfen-
tanil auf die schmerzbezogene Aktivierung sensorischer Hirnregionen in Trägern der 118G Va-
riante ein neuroanatomisches Korrelat für die verminderte analgetische Wirkung von Opioiden 
in Trägern der Mutation dar. 
Im zweiten Schritt wurde die SII-Region, als eine Region, die die sensorische Komponente des 
Schmerzes kodiert, und der laterale Thalamus, als eine zentrale Schaltstelle für afferente nozi-
zeptive Reize, mittels molekularbiologischer Methoden auf Veränderungen der Rezeptorexp-
ression  ([
3H]-DAMGO-Saturierungsexperimente,  OPRM1  mRNA-Expressionsbestimmung  mit-
tels RT-PCR), der Rezeptor-Liganden-Affinität ([
3H]-DAMGO-Saturierungs- und Verdrängungs-
experimente) und der Rezeptor-Signaltransduktion ([
35S]-GTPγS-Bindungsexperimente) unter-
sucht. Dazu wurde post-mortem Hirngewebe von 22 Nichtträgern, 21 heterozygoten und 3 
homozygoten Trägern der µ-Opioidrezeptor Variante N40D entnommen. Die µ-Opioidrezepto-貀   ٣
  Deutsche Zusammenfassung   
 
73 
ren beider Hirnregionen unterschieden sich signifikant hinsichtlich ihrer Expression, Affinität 
und Funktion. So war in der SII-Region die OPRM1-mRNA-Expression um den Faktor 0,29-0,82 
(p=0,025) und die µ-Opioidrezeptor-Expression um den Faktor 0,51-1,16 (p=0,005) niedriger 
als im lateralen Thalamus. Die OPRM1-mRNA-Expression und die Rezeptorproteinexpression 
unterschieden sich in beiden Hirnregionen jedoch nicht zwischen Trägern und Nichtträgern der 
Variante  N40D.  Desweiteren  war  in  der  SII-Region  die  Rezeptoraffinität  zu  dem  µ-
Opioidrezeptor-spezifischen Agonisten [
3H]-DAMGO um den Faktor 1,07-2,14 (p=0,005) und 
die Potenz von DAMGO, die Rezeptor vermittelte Bindung des GTP Analogons [
35S]-GTPγS an 
das intrazellulär gebundene G-Protein zu erhöhen, um das 2,5-8,5 fache (p=0,004) niedriger als 
im lateralen Thalamus. Auch die Rezeptoraffinität zu [
3H]-DAMGO und die Potenz von DAMGO 
unterschied sich in beiden Hirnregionen nicht zwischen Trägern und Nichtträgern der Variante 
N40D. Obwohl die Rezeptorexpression in der SII-Region signifikant niedriger war als im latera-
len Thalamus, unterschieden sich beide Regionen nicht hinsichtlich der Nettozunahme der 
Rezeptor-gebundenen  [
35S]-GTPγS  Moleküle  nach  Stimulation  durch  DAMGO,  was  auf  eine 
verringerte µ-Opioidrezeptor-G-Protein-Kopplungseffizienz im lateralen Thalamus im Vergleich 
zur SII-Region schließen lässt. Die Unterschiede zwischen beiden Hirnregionen variierten dabei 
signifikant (p=0,008) zwischen Trägern und Nichtträgern der N40D Variante. Während die µ-
Opioidrezeptor-G-Protein-Kopplungeffizienz in der SII-Region von Nichtträgern der Variante um 
den Faktor 1,55-2,27 (p<0,001) höher war als im lateralen Thalamus, unterschied sie sich nicht 
in  Trägern  der  118G  Variante  (118AG:  Faktor  0,78-1,66,  p=0,36;  118GG:  Faktor  0,66-1,15, 
p=0,72). Diese Beobachtung lässt auf eine verringerte G-Protein-Kopplung des Rezeptors in der 
SII-Region von Trägern der 118G Variante schließen, welches die Unterschiede in der Dosisab-
hängigkeit  der  Opioideffekte  in  sensorischen  Hirnregionen  von  homozygoten  Trägern  der 
OPRM1 Variante 118G erklärt, die in den fMRI-Experimenten beobachtet wurden.  
Im letzten Schritt wurden die klinischen Konsequenzen der µ-Opioidrezeptor-Variante N40D 
für die analgetische Potenz und die therapeutische Breite von Opioiden mittels experimentel-
ler pharmakodynamischer Schmerz- und Atemdepressionsmodelle untersucht. Dazu wurden 
10 gesunden Nichtträgern, 4 heterozygoten und 6 homozygoten Trägern der µ-Opioidrezeptor 
Variante N40D vier verschiedene aufsteigende Konzentrationen Alfentanil (0, 33.33, 66.66 und 
100 ng/ml) infundiert. Bei jeder Alfentanilkonzentration wurde die Analgesie anhand elektri-
scher Schmerzstimulation am Mittelgelenk des linken Mittelfingers (5Hz Sinus mit Stromstär-
ken 0-20mA) und anhand chemischer Schmerzstimulation der Nasenschleimhaut (gasförmiges 
CO2; Reizdauer 200ms) gemessen. Die Atemdepression wurde mittels CO2 Rückatmung nach 飀٣
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Read und durch Aufnahme der Atemfrequenz bestimmt. Mit zunehmender Alfentanilkonzent-
ration am Wirkort (ZNS) nahm die Schmerztoleranz gegenüber den elektrischen Schmerzreizen 
bei hetero- und homozygoten Trägern der N40D Variante signifikant weniger stark zu als bei 
Nichtträgern (Faktor 0.454; p<0.05). Auch die Analgesie bei chemo-somatosensorischer Rei-
zung der Nasenschleimhaut war bei homozygoten Träger der Variante weniger stark ausgep-
rägt (Faktor 0.565; p<0.05). Alfentanil verursachte bei homozygoten Trägern des varianten 
118G-Allels eine signifikant geringere Atemdepression als bei heterozygoten Trägern oder bei 
Nichtträgern  der  Variante  (CO2-Rückatmung:  Faktor  0.416,  Atemfrequenzmessung:  Faktor 
0.222; p<0.01). Homozygote Träger des OPRM1 118A>G Polymorphismus benötigten ca. 2- bis 
4-fach höhere Alfentanilkonzentrationen, um dieselbe Analgesie, und ca. 10- bis 12-fach höhe-
re Konzentrationen, um die gleiche Atemdepression wie Nichtträger zu erreichen. Die thera-
peutische  Breite  von  Alfentanil  ist  daher  in  homozygoten  Trägern  des  OPRM1  118A>G-
Polymorphismus gegenüber Nichtträgern vergrößert. In Übereinstimmung mit bereits veröf-
fentlichten  Ergebnissen  anderer  Arbeitsgruppen  waren  heterozygote  Träger  abhängig  vom 
verwendeten Schmerzmodell wie die homozygoten Träger von einer verminderten Analgesie 
betroffen, litten aber im Gegensatz zu homozygoten Trägern unter der gleichen Atemdepres-
sion wie Nichtträger der Mutation. Dies deutet auf eine Verminderung der therapeutischen 
Breite von Opioiden in heterozygoten Trägern im Gegensatz zu den homozygoten Trägern hin. 
Eine abschließende Bewertung bezüglich der therapeutischen Breite in heterozygoten Trägern 
kann aber aufgrund der zu geringen Teilnehmerzahl an dieser Stelle nicht getroffen werden.  
Die Ergebnisse der Arbeit zeigen, dass die µ-Opioidrezeptor-Variante N40D eine regional be-
grenzte Verminderung der Signaltransduktionseffizienz des µ-Opioidrezeptors in verschiede-
nen Hirnregionen nach sich zieht. Dadurch wird bei Trägern der Variante N40D die schmerzhaf-
te Aktivierung sensorischer, in die Verarbeitung der Schmerzintensität einbezogener Hirnre-
gionen nicht ausreichend durch Opioidanalgetika unterdrückt. Bei unzureichender Schmerzstil-
lung muss deshalb in hetero- und homozygoten Trägern der Variante N40D die Konzentration 
von Opioidanalgetika um einen Faktor 2 – 4 erhöht werden, um die gleiche Analgesie wie bei 
Nichtträgern zu erreichen. Gleichzeitig sind bei homozygoten Trägern der N40D-Variante die 
atemdepressiven Wirkungen in stärkerem Ausmaß vermindert und es wird eine 10 – 12 mal 
höhere Opioidkonzentration benötigt, um die gleiche Atemdepression wie bei Nichtträgern zu 
erreichen. Wegen der demzufolge erhöhten therapeutischen Breite von Opioiden scheint eine 
Erhöhung der Opioidkonzentration zur Gewährleistung ausreichender Analgesie zumindest bei 
homozygoten Trägern klinisch unbedenklich zu sein. 貀٣
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9  Appendix 
9.1  Abbreviations 
[
35S]-GTPγS  Guanosine-5'-(γ-[
35S])-thiotriphosphate 
[
3H]-DAMGO 
3H-[D-Ala
2,N-MePhe
4,Gly-ol
5]-enkephalin 
°C  Temperature in degree Celsius 
ACTB  Gene coding for β-Actin 
ANOVA  Analysis of variance 
Asn  Asparagine 
Asp  Aspartic Acid 
bp  Base pair 
B0  Baseline response (e.g. basal binding) 
BMax  Maximum response (e.g. maximum binding) 
BSA  Bovine serum albumin 
cDNA  Copy DNA 
COMT  Gene coding for the Catechol-O-methyltransferase 
Conc.  Concentration 
D  Aspartic Acid 
DNA  Deoxyribonucleic acid 
dpm  Decays per minute 
DTT  Dithiothreit 
EC50  Effective concentration 50% (Conc. of agonist that provokes a response 
half way between the baseline (e.g. B0) and maximum response (e.g. 
BMax)) 
e.g.  For example 
EEG  Electroencelography 
EGTA  Ethylene glycol tetraacetic acid (chelating agent) 
fM  Femtomolar (fmol/l) 
fMRI  Functional magnetic resonance imaging 
g  Gramm 
GDP  Guanosine-5'-diphosphate 
GIRK  G-protein activated inwardly rectifying potassium (K
+) channel 
GTP  Guanosine-5'-triphosphate 
h  Hours 
H2O  Aqua purificata 
HCl  Hydrochloric acid 
IC50  Inhibitory concentration 50% (Basically the same as the EC50 but mainly 
used in competition binding experiments) 
i.e.  That is 
KD  Equilibrium dissociation constant  
LC-MS/MS  Liquid chromatographic tandem mass spectrometric 
M  Molar 
mg  Milligram 
MgCl2  Magnesium chloride 
min  Minutes 
msec  Milliseconds 
mM  Millimolar (mmol/l) ๒ 貀٣
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N  Asparagine 
ng  Nanogramm 
nM  Nanomolar (nmol/l) 
OPRM1  Gene coding for the μ-Opioid receptor 
PCR  Polymerase chain reaction 
RNA  Ribonucleic acid 
RT-PCR  Real time polymerase chain reaction  
SI  Primary somatosensory cortex 
SII  Secondary somatosensory cortex 
sec  Seconds 
SEM  Standard error of the mean 
SNP  Single nucleotide polymorphism 
t  Tesla 
Tris  Tris(hydroxymethyl)aminomethan 
μg  Microgram 
μl   Microliter 
μM  Micromolar (μmol/l) 骠٣
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